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ABSTRACT 
 
Sheryl Rubio Bowley 
 Insights from Structure-Function Studies of Variant Fibrinogen  
(Under the direction of Dr. Susan T. Lord)  
    
     Studies have linked fibrinogen and fibrin clot structure, strength and stability to 
cardiovascular diseases. Fibrinogen is a central participant in hemostasis, the maintenance of 
the delicate balance between clot formation and dissolution. During coagulation, thrombin 
converts soluble fibrinogen into insoluble fibrin polymer. Thrombin first cleaves 
fibrinopeptides A, exposing knobs “A” that spontaneously bind to holes “a” in another fibrin 
molecules forming “A:a” interactions. These interactions lead to the assembly of two parallel 
strands of fibrin molecules called protofibrils that are connected end-to-end by D:D 
interactions. Polymerization progresses with the lateral aggregation of protofibrils, during 
which, thrombin cleaves fibrinopeptide B exposing knobs “B” that bind to a complementary 
site called hole “b” in another molecule. This lateral aggregation of protofibrils form thicker 
fibers that grow, branch and form a network. 
     Although the development of the method for engineering variant fibrinogens has provided 
enormous information regarding critical residues in fibrin polymerization, the full impact of 
the mutations on polymerization is not complete without structural data. In this work, the 
molecular bases for the impairment seen in fibrinogen variants were studied by functional 
assays and structural analysis. Fibrinogens that target mutations in hole “a” were studied to 
characterize “A:a” interactions. Biochemical and structural data showed that electrostatic 
 iii
interactions in hole “a” facilitate the important first step in fibrin polymerization. While the 
critical role of “A:a” interactions are well-established, the importance of “B:b” knob-hole 
interactions had been a matter of great debate. In this study, structural and biochemical 
analyses of variant recombinant fibrinogen that has a mutation in hole “b” showed “B:b” 
interactions have little influence on fibrin polymerization. It is likely that the loss of 
fibrinopeptide B rather than the gain of “B:b” interactions modulate lateral aggregation 
during fibrin polymerization. The impact of D:D interactions in fibrin polymerization was 
also explored in this study. Using variant fibrinogen with mutation at the D:D interface 
patterned after those found in patients, the molecular basis for the functional impairment of 
this abnormal fibrinogen was examined by combined biochemical and structural studies. 
Results showed that charge complementarities at the D:D interface during end-to-end 
association of fibrin molecules is important; that D:D interactions may be interdependent 
with other interactions in fibrin. 
     These studies provided better understanding of the mechanism of fibrin formation which 
will likely enhance our ability to diagnose and design therapeutics for bleeding and 
thrombotic disorders. 
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 Fibrinogen Function and Physiology 
    Synthesized primarily in liver cells, fibrinogen is a plasma glycoprotein that has diverse 
biological activities. Fibrinogen circulates in the blood at concentrations of 1.5-3 mg/mL  and 
is a central participant in hemostasis, the maintenance of the delicate balance between clot 
formation and dissolution (1). When the vasculature is compromised, the initial phase of clot 
formation involves fibrinogen serving as a molecular link that mediates platelet aggregation 
forming a plug that stops blood flow. Subsequently, the enzyme thrombin converts 
fibrinogen into fibrin matrix that gives the clot shape, strength, flexibility and stability (2). 
Fibrin also plays a key role in the subsequent dissolution of the clot. Fibrinolysis is initiated 
when tissue-type plasminogen activator (tPA) and plasminogen bind to fibrin. The activation 
of plasminogen to plasmin by tPA is stimulated by its substrate, fibrin. Plasmin then digests 
the fibrin mesh, thereby, dissolving the clot (3). 
     Apart from its role in hemostasis, fibrinogen is also involved in inflammation, wound 
healing, cell migration and cell proliferation through its variety of interactions (4). 
Fibrinogen binds to integrin receptors expressed on leukocytes, macrophages and monocytes 
that contribute to the inflammatory response. Binding of fibrinogen to other receptors 
including intracellular adhesion molecule 1 (ICAM-1) and vascular endothelial cadherin 
(VE-cadherin) promotes cell adhesion and migration. Interactions of fibrinogen with 
fibronectin and growth factors also regulate cell adhesion and migration during wound 
healing. Fibrinogen has also been shown to bind proteins expressed by common bacteria that 
promote adhesion suggesting that fibrinogen may have a role in microbial pathogenesis.  
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1.2 Fibrinogen Structure 
     Given the ability of fibrinogen to act in diverse biological settings, it is not surprising that 
is also has a complex structure. Fibrinogen is a 340-kDa dimeric glycoprotein composed of 
three polypeptide chains: (Aα, Bβ, γ)2  (1). Each half of the dimeric molecule consists of 
three non-identical polypeptide chains: Aα (610 amino acids), Bβ (461 amino acids) and γ 
(411 amino acids) held by a network of 29 disulfide bonds. The six chains are folded into 
three distinct structural regions: two distal D regions linked by coiled-coil connectors to one 
central E region forming a trinodular structure as shown in Figure 1.1 (A). The first glimpse 
of the fibrinogen molecule obtained by Hall and Slater in 1959 using transmission electron 
microscopy shown in Figure 1.1 (B) revealed a trinodular structure (5). The central E region 
contains the N-termini of all six chains which include two sets of fibrinopeptides, FpA and 
FpB, from the N-terminus of the Aα- and Bβ- chains, respectively. The two distal D nodules 
contain the independently-folded C-terminal regions of the Bβ- and γ-chains, called βC and 
γC, respectively. The C-termini of the Aα-chains, called αC, exit the D nodule as a fourth 
helix to the coiled coil, and then loop back towards the center where they may noncovalently 
interact with each other, with the E nodule or extend freely into solution.  
     Over the decades, attempts to obtain a high resolution crystal structure of human 
fibrinogen have been unsuccessful. It is thought that the inherent flexibility of fibrinogen 
regions, specifically the αC-domains, contributes to poor crystal growth of human 
fibrinogen.  
     Because native fibrinogen is difficult to crystallize, two approaches have been taken in the 
crystallographic analysis of fibrinogen. One group of investigators constructed the 30-kDa 
γC-domain expressed in yeast and later solved the crystal structure to 2.1 Å shown  in  Figure 
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 Figure 1.1 The structure of fibrinogen. (A) Cartoon representation of the fibrinogen 
molecule showing the distal D regions and the central E region connected by the coiled-coil 
adapted from (3). Chains are color-coded with the Aα-chain in blue, Bβ-chain in green and 
the γ-chain in red. (B) The first transmission electron micrograph of the fibrinogen molecule 
showing the trinodular structure adapted from (5). Individual fibrinogen molecules are 
indicated by the red arrow.  
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Figure 1.2 The structure the γC-domain in fibrinogen. This 30-kDa recombinant γ-
module of fibrinogen was synthesized in yeast. The structure shows the location of the high 
affinity calcium binding site (orange sphere), referred to as γ1 Ca2+. Also shown is the knob 
“A” peptide mimic, GPRP (magenta sticks), bound to hole “a” forming. The figure was made 
using PDB code 2FIB (6 ) using Pymol (Delano Scientific, CA). 
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 1.2 (6). The other group worked on a proteolitically-derived 86-kDa fragment D consisting 
of the βC and γC globular domains and part of the coiled coil region. They also obtained the 
structure of the fibrin degradation product containing FXIIIa-crosslinked double-D. Both 
these structures are shown in Figure 1.3 (7). In 2000, Brown et al. (8) reported the ~4 Å  
structure of bovine fibrinogen that was selectively proteolyzed to remove the flexible αC-
domains. A year later, Yang et al. (9), published the structure of chicken fibrinogen at 2.7 Å 
with intact αC-domains that were significantly shorter than the human counterpart (Figure 
1.4). Nevertheless, the full structure of the αC-domains in chicken fibrinogen was still not 
possible to build into the electron density supporting earlier suggestions that the αC-domains 
are flexible and intrinsically disordered. These full length fibrinogen structures showed the 
planar sigmoidal shape of fibrinogen earlier proposed from electron micrograph images. In 
addition, a high-resolution structure of the dimeric N-terminal portion of the molecule, 
fragment E, from bovine fibrinogen was solved to 1.4 Å (Figure 1.5) (10). In 2002, 
Kostelansky et al. (11) reported the crystal structure of human fragment D obtained from 
recombinant fibrinogen expressed in Chinese hamster ovary (CHO) cells and showed that 
recombinant fibrinogen is structurally similar to plasma fibrinogen (Figure 1.6). This finding 
is important since engineered recombinant fibrinogen preparations are extremely useful tools 
in identifying residues critical to fibrinogen function. This observation later paved way to the 
successful crystallization of variant recombinant fibrinogens with specific mutations.  
     Many of these crystal structures were obtained with the fragments complexed with 
tetrapeptides patterned after the thrombin-exposed N-termini of the central E region. Thus, 
these studies have revealed many of the possible interactions that mediate thrombin-
catalyzed fibrin polymerization. In addition, calcium binding sites in fibrinogen were located.  
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Figure 1.3 The structure human fibrinogen fragment D and double-D. (A) The structure 
shows fragment D from human plasma fibrinogen obtained by controlled trypsin digestion. 
The gray dots show the location of the carbohydrate moiety in the βC-domain. (B) Crystal 
structure of the crosslinked human double-D fragment. The structure shows additional 
calcium binding sites (orange spheres) as well as the location of holes “a” and “b”, inferred 
from binding of GPRP (magenta sticks) and GHRP (yellow sticks), respectively. The 
location of the covalent crosslink between γ398Gln and γ406Lys was not visible in the 
structure. Figure A and B were generated from PDB entry 1FZA and 1FZB, respectively (7) 
using Pymol (Delano Scientific, CA). 
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Figure 1.4 The structure bovine and chicken fibrinogen. The full length structures of (A) 
bovine and (B) chicken fibrinogen showing the sigmoidal shape of the molecule. The 
structures also show glycosylation sites in gray spheres. Figure (A) was adapted from (8) and 
(B) was generated from PBD code 1EA3 (9) and displayed using Pymol (Delano Scientific, 
CA). 
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Figure 1.5 Crystal structure of fragment E. The structure shows the central E region of the 
fibrinogen molecule that contains parts of the N-termini of all three chains. The portion 
showing the fibrinopeptides and the knobs are not seen in the structure. The α-chain is in red, 
β-chain is in green and γ-chain is in blue. The figure is generated from PDB code 1JY2 (10) 
and displayed using Pymol (Delano Scientific, CA). 
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Figure 1.6 Crystal structure human recombinant fragment D. The structure shows a 
fragment arising from controlled tryptic digestion of human recombinant fibrinogen that 
yielded fragment D. The recombinant protein was expressed in CHO cells. Calcium ions are 
shown as orange spheres. Knob “A” peptide mimic, GPRP (magenta sticks), was bound to 
hole “a” while knob “B” peptide mimic, GHRP (yellow sticks), was bound to hole “b”. The 
carbohydrate in the βC-domain is shown as gray spheres. The α-chain is in red, β-chain is in 
green and γ-chain is in blue. The figure is generated from PDB code 1LTJ (11) and displayed 
using Pymol (Delano Scientific, CA). 
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1.3 Formation of Fibrin 
     1.3.1 The coagulation cascade.  Fibrin clot formation in vivo is the culmination of a 
sequence of events collectively known as the coagulation cascade shown in Figure 1.7 (12).  
This process involves sequential stages: initiation, amplification, and propagation. During 
vascular injury, tissue factor-bearing cells such as fibroblasts become exposed to blood. 
Initiation of coagulation involves exposure of active tissue factor (TF) to plasma which forms 
a complex with circulating active factor VII (VIIa/TF complex). This complex then converts 
factors IX and X into their active forms (IXa and Xa). Factor Xa in turn associates with Va 
on the cell surface forming the Xa/Va complex that activates a small amount of factor II 
(prothrombin) to IIa (thrombin). During amplification, this small-scale thrombin activates 
other cofactors (V and VIII) as well as platelets. Propagation involves large-scale thrombin 
generation at the platelet surface where factor IXa associates with VIIIa forming the tenase 
complex which generates factor Xa. Factors Xa and Va forms the prothrombinase complex 
that efficiently generates the large thrombin burst. The large-scale thrombin burst is 
responsible for the conversion of soluble circulating fibrinogen into the  insoluble fibrin 
polymer. 
 
    1.3.2 Model of fibrin polymerization.  The details of how fibrin units pack together to form 
the clot has been the subject of studies in the last 50 years. The advent of sophisticated 
biophysical methods, single-molecule measurements of interactions, X-ray crystallography 
complemented with studies of variant recombinant fibrinogen, has greatly advanced our 
understanding of fibrin polymerization. 
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Figure 1.7 The coagulation cascade. The figure shows the different component of the 
coagulation cascade. The culmination of this event is the production of large amount of 
thrombin (IIa) which converts fibrinogen to fibrin clot. This figure was modified from (12). 
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D:D interactions  
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Proposed mechanism of fibrin polymerization. Thrombin cleaves FpA in 
fibrinogen exposing knobs “A” that bind to holes “a” in γC domain forming “A:a” 
interactions. These interactions mediate protofibril formation. Thrombin then cleaves FpB 
exposing knobs “B” that bind to holes “b” in the βC domain forming “B:b” interactions. This 
event leads to the lateral aggregation of protofibrils leading to thicker fibers. 
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   In the last stage of blood coagulation, the serine protease thrombin cleaves the amino-
termini  of    the   Aα-   and  Bβ-chains   at   the  central   E  region  of  fibrinogen,  releasing  
fibrinopeptides, FpA and FpB, respectively, forming fibrin monomers (1). Removal of FpA 
(Figure 1.8) exposes a new N-terminus in the α-chain, called knob “A” which starts with the 
sequence Gly-Pro-Arg. Knob “A” binds noncovalently to a complementary polymerization 
hole in the γC-domain called hole “a” forming “A:a” interactions which align the fibrin 
monomers into half-staggered, two-stranded protofibrils. The end-to-end association of fibrin 
monomers involves abutting γC-domains in the D nodules of adjacent fibrin molecules 
forming D:D interfacial interactions (Figure 1.8). Protofibrils are also stabilized by covalent 
γ-γ crosslinks mediated by the transglutaminase enzyme factor XIIIa. Crystal structures of 
chicken fibrinogen, fragment D derived from tryptic digestion of human fibrinogen and 
recombinant γ-module showed that the peptide mimic, GPRP forms H-bonds with residues 
γ364Asp, γ330Asp, γ329Gln and γ340His found in hole “a” (6, 7, 9, 11). This peptide also 
inhibits polymerization and cause dissolution of clots (13, 14).  
     FpB release occurs primarily during growth of protofibrils leading to the exposure of a 
new N-terminus in the β-chain called knob “B” which starts with the sequence Gly-His-Arg. 
Similar to knob “A”, knob “B” binds to a complementary site in the βC-domain called hole 
“b” forming “B:b” interactions. Crystal structures showed the peptide mimic GHRP interacts 
with residues residues Bβ397Glu, Bβ398Asp and Bβ432Asp in hole “b” (6, 7, 9, 11). After 
FpB removal the protofibrils laterally associate and branch to form a dense fibrin network 
suggesting “B:b” interactions are important in lateral aggregation (15). Nevertheless, fibrin 
clots can still be formed by removal of FpA only, as can be demonstrated with various snake 
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venom enzymes like batroxobin and reptilase (15). Thus, there is controversy surrounding the 
role of “B:b” interactions in fibrin polymerization. 
 
1.4 Recombinant Fibrinogen 
     Because plasma fibrinogen binds proteins like factor XIII, fibronectin and plasminogen, 
plasma-derived fibrinogen often co-purify with these proteins even with extensive 
purification procedures. The natural heterogeneity of plasma fibrinogen due to variations in 
mRNA processing, posttranslational modification and proteolysis in the circulation also 
makes plasma preparation not ideal for well-controlled experiments. The use of 
homogeneous, recombinant fibrinogen circumvents most of these problems and also permits 
synthesis of variant fibrinogens. This system is a powerful tool in identifying residues critical 
to normal fibrin polymerization. Recombinant fibrinogens can also be used to study and 
understand the details involved in dysfibrinogenemia cases which are abnormalities 
associated with genetic variants. The vast majority of dysfibrinogenemia patients are 
heterozygous to the mutation which means both the normal and abnormal copies are present 
in their plasma. The recombinant system allows homogeneous mutated fibrinogen to be 
synthesized and used to determine the molecular basis for the functional impairment. It is 
important to note that plasma and recombinant fibrinogen molecules are essentially the same 
as shown by multiple experiments (16). 
     Normal recombinant fibrinogen is synthesized in CHO cells which harbor plasmids 
containing the cDNAs for all three chains of human fibrinogen (17). Variant fibrinogens are 
produced by site-directed mutagenesis in either Aα, Bβ or γ plasmid. The altered plasmid is 
then transfected into CHO cells containing the plasmids that encode the other unaltered 
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chains. When all three chains are present, CHO cells can synthesize and secrete fibrinogen. 
Large-scale protein production is carried out in roller bottles containing serum-free media. 
The recombinant fibrinogen is purified by a two-step procedure using ammonium sulfate 
precipitation and immunoaffinity chromatography. The purified protein is then analyzed by 
SDS-PAGE to ensure proper assembly before performing biochemical assays. 
 
1.5 Significance and Goals of this Work     
     Studies have linked fibrinogen and fibrin clot structure, strength and stability to 
cardiovascular diseases (18, 19). It is therefore of great interest to understand the mechanism 
of fibrin polymerization. These studies will enhance our ability to diagnose disease 
conditions and design therapeutic approaches for bleeding and thrombotic disorders. 
     Although the development of the method for engineering variant fibrinogens has provided 
enormous information regarding critical residues in fibrin polymerization, it is still not 
possible to fully evaluate the impact of mutations on fibrinogen structure and the 
consequences on polymerization. It is still unclear whether the mutations introduced in 
fibrinogen disrupt specific interactions that are critical for function or whether these 
mutations cause global changes in the structure that result in functional abnormalities. Thus, 
one of the goals of my dissertation research was to further characterize “A:a” interactions by 
biochemical and structural approaches using γ364Asp variants that are patterned after 
reported dysfibrinogens, described in Chapter 2. These findings were published recently (20). 
     While the basics of the conversion of fibrinogen into fibrin have been known for a long 
time, there is still a debate surrounding the roles of the two major pairs of polymerization 
holes. More specifically, it is still unclear whether or not “B:b: interactions are critical for 
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normal fibrin polymerization. Studies have shown that removal of FpB enhances lateral 
aggregation of protofibrils (15, 21). However, fibers that look normal are produced from 
cleavage of FpA alone suggesting that protofibrils with just “A:a” and no “B:b” are able to 
aggregate laterally to make fibers (15). Thus, “B:b” interactions are not necessary for lateral 
aggregation. Another goal of my research is to clarify the role of “B:b” knob-hole 
interactions presented in Chapter 3. This chapter describes surprising and very informative 
biochemical and structural data done on variant fibrinogen BβD432A with a mutation in hole 
“b”.  
     In addition to “A:a” and “B:b” binding, there are other important fibrin interactions that 
are not as extensively studied as the knob-hole interactions. During the alignment of fibrin 
monomers into protofibrils, surface-exposed regions on the γC-domain of two adjacent 
molecules abut each other to form the D:D interface (7). These D:D interactions do not bury 
significant surface area and involve only a few potential hydrogen bonds and no obvious salt 
bridges. Nevertheless, a significant number of dysfibrinogenemia cases characterized by 
severe bleeding or predisposition to thrombosis, involve residues in this interface (3). 
Without structural data, it is difficult to determine how mutation at the interface impacts the 
overall structure and function of the molecule. The third goal of my dissertation research is to 
understand the molecular basis for the impairment associated with mutations at the D:D 
interface. Chapter 4 focuses on remarkable findings obtained from studies of the fibrinogen 
variant γN308K, another variant patterned from dysfibrinogenemia cases involving the D:D 
interface.  
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POLYMERIZATION-DEFECTIVE FIBRINOGEN VARIANT γD364A  
BINDS KNOB “A” PEPTIDE MIMIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Reproduced with permission from: Bowley, S. R., Merenbloom, B. K., Okumura, N., Betts, 
L., Heroux, A., Gorkun, O. V., and Lord, S. T. (2008) Polymerization-defective 
fibrinogen variant gammaD364A binds knob "A" peptide mimic, Biochemistry 47, 
8607-8613. 
2.1 Introduction     
     Fibrinogen is a plasma glycoprotein consisting of a dimer of three polypeptide chains, 
Aα, Bβ and γ. The molecule is folded such that the N-termini of all six chains originate at the 
center of the molecule, called the E nodule. The C-termini of the chains extend from the 
center as two pairs of three chains. The C-termini of the Bβ and the γ  chains fold into 
independent globular regions that are located at the peripheral ends of the molecule forming 
two identical D nodules. The E and D regions are linked by α-helical coiled-coil connectors 
forming a trinodular structure (1). Laser tweezers-based force spectroscopy data suggest that 
the central E region in fibrinogen forms intramolecular interactions with the two Aα carboxyl 
termini (αC domains) (2).  
     The conversion of fibrinogen to fibrin monomer is catalyzed by the enzyme thrombin, 
which cleaves two pairs of short fibrinopeptides from the N-termini of the Aα (called FpA) 
and Bβ (called FpB) chains, exposing sites designated as knobs “A” and “B”, respectively 
(3). The exposed knob “A” binds to a complementary binding site in the γ-chain called hole 
“a” forming “A:a” interactions (3, 4). These interactions lead to a double-stranded fibrin 
protofibril with a half-staggered overlap between molecules in different strands (5). Cleavage 
of FpB occurs primarily during protofibril growth, leading to the binding of knob “B” to a 
complementary binding site in the β-chain called hole “b” forming “B:b” interactions (6). 
This event enhances the rate and extent of lateral aggregation of protofibrils and leads to the 
formation of thicker fibers (7).  
     The location of the binding holes and possible models for knob-hole interactions are 
known from X-ray crystallographic studies using two synthetic peptide analogs of knobs “A” 
and “B”. When fibrinogen fragment D and double-D are crystallized in the presence of both 
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peptide analogs, the knob “A” peptide mimic, GPRP, forms H-bond interactions with 
residues γ364Asp, γ330Asp, γ329Gln and γ340His found in hole “a”. In the same manner, the 
knob “B” peptide mimic, GHRP interacts with residues Bβ397Glu, Bβ398Asp and 
Bβ432Asp in hole “b” (8, 9). High resolution structural data also showed that the γ- and β-
modules, containing the binding holes, are highly homologous (8, 9). 
     The significance of the interactions between GPRP and residue γ364Asp is known from 
studies of two previously identified dysfibrinogens with substitutions at γ364. The 
substitution of histidine for γ364Asp (Fibrinogen Matsumoto I) was found in an individual 
who is heterozygous for the mutation (10). The patient showed prolonged clotting time, 
although no overt coagulation defect, neither bleeding nor thrombosis. Another individual, 
who presented with numerous episodes of deep venous thrombosis, was found to be 
heterozygous for the valine mutation, γD364V (Fibrinogen Melun) (11).  Previous works 
have used recombinant variant fibrinogens (12, 13) to show that the residue γ364Asp is 
critical to normal thrombin-catalyzed polymerization. Nevertheless, the molecular basis for 
the polymerization impairment in these γ364Asp variants remains unclear. 
     In the current study, we examined the molecular nature of “A:a” interactions in γ364Asp 
variants. We crystallized fragment D from γD364A in the presence of the synthetic peptides 
GPRP and GHRP and solved the 2.6 Å structure, which we called rfD-γD364A+GP as the 
crystals contained only GPRP. We used proteolytic fragmentation to study the binding of 
GPRP in γD364A, γD364H and γD364V. Our data suggest that “A:a” interactions are weak 
in γD364A and absent in both γD364H and γD364V. While our structural data showed that 
the alanine substitution in γD364A does not alter hole “a” and this variant still binds knob 
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“A”, biochemical data suggest that the loss of γ364Asp weakens “A:a” interactions and 
diminishes electrostatic steering that may be critical for normal fibrin polymerization.          
                                                    
2.2 Experimental Methods 
      2.2.1 Reagents. All chemicals were of reagent grade and were purchased from Sigma-
Aldrich (St. Louis, MO), unless specified otherwise. The peptides GPRP and GHRP were 
synthesized by the Protein Chemistry Laboratory at the University of North Carolina at 
Chapel Hill (Chapel Hill, NC). Cell culture media with normal recombinant fibrinogen was 
obtained from the National Cell Culture Center (Minneapolis, MN). Cyanogen bromide-
activated Sepharose 4B and Superose 6 resins were purchased from Amersham Biosciences 
(Piscataway, NJ). Monoclonal IF-1 antibody was purchased from Kamiya Biomedical 
(Seattle, WA). 
 
      2.2.2 Expression and Purification of Recombinant Fibrinogen γD364A, γD364H and 
γD364V. Normal and variant recombinant fibrinogens γD364A, γD364H and γD364V were 
synthesized in CHO cells as described previously (12, 13). Large scale protein expression 
was carried out in serum-free medium in roller bottles. Media containing secreted fibrinogen 
were harvested periodically. After addition of protease inhibitors, the media were stored at -
20oC  (14).  
     Recombinant fibrinogen was purified as described (15). Briefly, fibrinogen was 
precipitated from the media with ammonium sulfate in the presence of a cocktail of protease 
inhibitors. The precipitate was resuspended in buffer containing 10 mM CaCl2 and applied to 
a Sepharose 4B column coupled with the fibrinogen specific monoclonal antibody, IF-1. 
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Fibrinogen was eluted from the column with buffer containing 5 mM EDTA; dialyzed 
against HBS (20 mM HEPES, pH 7.4, 150 mM NaCl) and 1 mM CaCl2 for one exchange and 
then extensively dialyzed against HBS; and stored at -80oC. The integrity of the polypeptide 
chains and purity of the recombinant protein were analyzed by SDS-PAGE under reducing 
and nonreducing conditions following the method of Laemmli (16). 
 
      2.2.3 Preparation and Purification of Fragment D. Fragment D was prepared from 
γD364A fibrinogen by controlled trypsin digestion, according to the method used for normal 
recombinant fibrinogen (9). Briefly, CaCl2 was added to 9 mg of γD364A (final 
concentration of 1.8 mg/mL) in HBS to a final concentration of 20 mM.  Digestion was 
initiated by adding 50 μL of immobilized TPCK Trypsin (Pierce Biotechnology Inc., 
Rockford, IL). The reaction was allowed to proceed over a period of days at room 
temperature until SDS-PAGE revealed bands that corresponded to the molecular weights of 
fragments D and E.  Digestion was stopped by removing the trypsin beads with 
centrifugation at 3000 rpm (Sorvall RC-3) for 10 min.  
     Fragment D was purified from the γD364A digest by lectin affinity chromatography based 
on the previously described method (17, 18). Briefly, the digest was loaded onto a 
ConcanavalinA-Sepharose column equilibrated with 10 mM Tris-HCl, pH 7.4 and 1 M NaCl 
(loading buffer). Fragment E was retained on the column while fragment D was eluted. The 
column was washed extensively with the loading buffer until all fragment D was collected in 
the eluate. Purified fragment D from γD364A was dialyzed against 50 mM Tris-HCl, pH 7.4, 
concentrated a 100-fold with a centrifugal filter device (50 kDa MW cutoff, Millipore Corp., 
Billerica, MA) and stored at 4oC.  
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        2.2.4 Crystallization of Fragment D from γD364A. Purified γD364A fragment D at 6.8 
mg/mL was co-crystallized with a mixture of 20 mM GPRP and 4 mM GHRP by sitting-drop 
diffusion at 4oC as described (9, 19). These peptide concentrations were tested after attempts 
at crystallizing with 4 mM of both peptides failed. Crystals were grown from drops 
containing 3 μL of fragment D/peptide in 50 mM Tris-HCl, pH 7.4, mixed with an equal 
volume of crystallant solution in the well which contained 50 mM Tris-HCl, pH 8.5, 2 mM 
NaN3, 12.5 mM CaCl2 and 9 % (w/v) PEG 3350. Single crystals appeared within days 
following streak seeding with crystals of normal recombinant fragment D (rfD) without 
added peptides.  
 
      2.2.5 X-ray Diffraction Data Collection and Structure Determination. Data collection for 
crystals of fragment D from recombinant γD364A fibrinogen (rfD-γD364A+GP) was carried 
out at 100 K using beamline X29 at the National Synchrotron Light Source at Brookhaven 
National Laboratory. A single crystal was selected and soaked in the same crystallant 
solution with 20% (v/v) glycerol, 20 mM GPRP and 4 mM GHRP. The crystal was then 
looped and flash-frozen in liquid nitrogen. Diffraction data were processed with DENZO and 
ScalePack (20).  
     The structure of the variant was solved by rigid body minimization followed by simulated 
annealing using the rfD structure without peptides bound (PDB code: 1LT9) as a starting 
model. The resulting model was refined using CNS (21)  and the model was improved by 
manual fitting in the program O (22) using sigmaA-weighted |2Fo - Fc| and |Fo - Fc| electron 
density maps (23). Several cycles of least square minimization, simulated annealing and 
individual temperature factor refinement applying weak non-crystallographic restraints in the 
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first cycles were done before water molecules were added to complete the model. 
Furthermore, cis-peptide bonds were added at positions Bβ407 and γ339. After all these 
refinement steps, the Rcrystal and Rfree converged to the values reported in Table 2.1.   
  
     2.2.6  Plasmin Protection Assay. Normal recombinant or variant fibrinogens (0.25 
mg/mL) in HBS buffer containing 5 mM CaCl2, 5 mM EDTA, 4 mM  or 20 mM GPRP 
(supplemented with 5 mM EDTA) were incubated with 4.8 μg/mL plasmin (Haematologic 
Technologies, Inc., Essex Junction, VT)  for 4 h at 37oC. The reactions were stopped by 
adding SDS-PAGE loading dye and heating at 100oC for 5 min. The plasmin digests were 
then analyzed on 7.5% gels that were stained with Coomassie brilliant blue. 
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Table 2.1:       Crystallographic Data and Refinement Statistics 
Data Statistics 
     resolution (Å) 50.0 - 2.6 
     space group P212121 
     cell constants (Å) a = 89.8  
b = 94.9 
c = 225.7 
     molecules/asymmetric unit 2 
     total observations 257228 
     unique reflections 66878 
     mean redundancy 3.8 
     Rsyma (%) (highest shell) 11.8  (31.1) 
     completeness (%) (highest shell) 82.4 (94.2) 
     mean I/σ (highest shell) 13.7 (4.8) 
Refinement Statistics 
     Rcrystb (%) 22.1 
     Rfree c (%) 26.4 
     average B factor (Å2) 37.3 
     number of model atoms  10618 
     number of solvent sites 446 
RMS deviations from ideals  
     bond length (Å) 0.006 
     bond angles (deg) 1.24 
a Rsym = Σ|I - 〈I〉|, where I is the observed intensity and 〈I〉 is the 
average intensity of multiple symmetry-related observations of that 
reflection. b Rcryst = Σ(|Fobs|- |Fcalc|)/Σ|Fobs|, where Fobs  and Fcalc are 
the observed and calculated structure factors, respectively. c Rfree is 
the R-factor based on data withheld from structural refinement. 
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2.3 Results 
    2.3.1 Structure of rfD-γD364+GP. We obtained high quality diffraction data with the 
γD364A fragment D crystallized in the presence of both GPRP and GHRP and were able to 
solve the structure at 2.6 Å. Because only GPRP was found in the crystal structure, we called 
this rfD-γD364A+GP.  
     The space group and unit cell dimensions of rfD-γD364A+GP were isomorphous to those 
of normal rfD in the presence and absence of peptides;  thus we solved the structure of the 
variant by rigid body minimization followed by simulated annealing using the rfD structure 
(PDB code: 1LT9) as a starting model. A total of 653 amino acid residues in each molecule 
of the asymmetric unit (α129-190, β161-458 and γ102-394) were elucidated from the 
electron density. The substitution of the Asp to Ala at γ364 was evident. Structure alignment 
of the normal and γD364A fragment D showed excellent agreement with RMSD of 0.45 Å 
over the aligned Cα-atomic positions, showing that the global structure of rfD-γD364A was 
not changed by the alanine substitution. Moreover, we found two calcium ions bound in the 
γ1 and β1 sites, as was observed previously for recombinant fragment D with both GPRP and 
GHRP (rfD-BOTH) (9). 
     
      2.3.2 Peptide Binding in rfD-γD364A+GP. A surprising feature of the rfD-γD364A+GP 
structure was the presence of GPRP in hole “a” (Figure 2.1). We had anticipated that the loss 
of the ionic interaction between the aspartate side chain and the free amino group of GPRP 
would deter peptide binding. Nevertheless, the peptide in hole “a” of the γ-chain was evident 
in the calculated |2Fo - Fc| and |Fo - Fc| electron density maps.   
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Figure 2.1 GPRP was bound to hole “a” in the γ-chain of γD364A. The |Fo - Fc| electron 
density around the peptide (brown) was contoured at 3.0σ and is shown as gray mesh. The γ1 
calcium-binding site located near hole “a” is shown as magenta sphere. Figure was displayed 
using Pymol (Delano Scientific, CA). 
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     We compared the interactions of the N-terminal glycine of GPRP in rfD-γD364A+GP to 
other known structures with the peptide bound to hole “a” (8, 9, 24). In all the structures 
shown in Figure 2.2, the carboxyl backbone of glycine forms H-bonds with the nitrogen 
backbones of γ340His and γ339Cys while the free amino group interacts with the nitrogen 
side chain and carboxyl backbone of γ340His.  Additionally, the positively charged free 
amino group of GPRP forms ionic interaction with the negatively charged carboxylate side 
chain of γ364Asp. This ionic interaction is lost in γD364A. 
     It is also notable that GPRP, and not the knob “B” peptide mimic GHRP, was bound to 
hole “b” in the β-chain. This was evident from the presence of a negative difference map  
around the histidine side chain (data not shown) when GHRP was modeled in hole “b”; in 
contrast, GPRP modeled at this site fit well with the electron density map (Figure 2.3). We 
conclude that 20 mM GPRP was sufficient to prevent binding of GHRP at 4 mM to fragment 
D.  This non-canonical “A:b” interaction was also seen in the structure of recombinant 
fibrinogen variant γD298,301A fragment D  (rfD-γD298,301A+GP) when crystallized in the 
presence of only GPRP (17). This implies that “A:b” interactions are possible during fibrin 
polymerization but the circumstances at which they occur and their significance are 
unknown. 
 
     2.3.3 Impact of the γD364A Substitution to Hole “a”.  Gross visual comparison of the 
normal rfD+BOTH and rfD-γD364A+GP structures (Figure 2.4A) revealed a roomier hole 
“a” in γD364A than in normal fibrinogen. In a detailed comparison, we found no differences 
in   the  position  or  orientation  of  any residue within  4.5 Å  of  the  peptide  (Figure 2.4B).  
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Figure 2.2 Interaction of the N-terminus of GPRP with hole “a” seen in various crystal 
structures.  The peptide in each structure is shown in balls and sticks. The structure  in cyan 
is obtained from normal recombinant fragment D with peptides bound, rfD+BOTH (1LTJ). 
The structure in blue corresponds to the crosslinked DD fragment with peptides bound 
(1FZC) while the structure in magenta is from the C-terminal 30-kDa γ-chain fragment with 
GPRP (2FIB). The rfD-γD364A+GP (3BVH) structure is shown in yellow. Dashed lines 
show interactions between the peptide and hole “a” residues. In rfD-γD364A+GP structure, 
the ionic interaction between γ364Asp and the free amino group of GPRP is lost. Figure was 
displayed using Pymol (Delano Scientific, CA). 
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Figure 2.3 GPRP was bound to hole “b” in the β-chain. In the presence of 4 mM GHRP 
and 20 mM GPRP, the latter was bound to hole “b”. The |Fo - Fc| electron density around 
GPRP (brown) was contoured at 3.0σ and is shown as gray mesh. The β1 calcium-binding 
site located near hole “b” is shown as magenta sphere. Figure was displayed using Pymol 
(Delano Scientific, CA). 
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 Figure 2.4. Comparison of hole “a” in rfD+BOTH and rfD-γD364A+GP. Panel A: GPRP 
bound to hole “a” is shown in orange. Gross inspection shows that γD364A makes a roomier 
hole “a”. Panel B: The set of residues forming polar and hydrophobic contacts with the 
GPRP is the same for normal and γD364A fragment D. Note that the alanine substitution did 
not introduce significant changes within residues in the hole. Panel C: The highly conserved 
γ338Lys-γ339Cys-γ340His triad that supports peptide binding is not altered in γD364A. 
Figure was displayed using Pymol (Delano Scientific, CA). 
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Moreover, the alanine substitution did not alter the positions of residues γ338Lys-γ339Cys-
γ340His, a triad of polar interactions that contribute to the stability of GPRP  binding  (Figure       
2.4C). Indeed, we found a cis-peptide bond between γ338Lys-γ339Cys, as has been seen in 
the structure of a 30-kDa C-terminal fragment of γ-chain (24), all other fragment D and 
crosslinked double D structures (8, 9, 17, 25, 26).  As is true for many protein structures (27), 
this cis-peptide bond in fibrinogen is located in a functionally important region of the 
molecule. Here it allows the γ339Cys backbone nitrogen to interact with the carbonyl group 
of glycine in GPRP.  We also examined the position of γ363Tyr.  Doolittle et. al. recently 
noted a conformational change in γ363Tyr-γ364Asp associated with GPRP binding (28). 
Specifically, when hole “a” is occupied, γ364Asp shifts slightly to interact with the peptide 
while γ363Tyr moves ~3 Å towards the arginine of GPRP forming favorable amino-aromatic 
interactions (29).  In the γD364A structure, there was no shift in the alanine side chain.  
Nevertheless, γ363Tyr in the γD364A structure was positioned as it is in the peptide bound 
structure of the normal protein, rfD-BOTH, forming amino-aromatic interactions with the 
peptide arginine. Our data suggest that the conformational change in γ363Tyr, which is seen 
in the presence of peptide, is independent of γ364Asp.   
     We also compared the charge distribution in hole “a” of γD364A and rfD-BOTH (Figure 
2.5). As noted from the earlier crystal structure of the C-terminal 30-kDa γ-chain fragment 
(30), loops surrounding the hole “a” region provide large areas of negatively charged surface. 
Loop γ316-324, for instance, provides a surface accessible negative electrostatic potential. 
This loop contains γ318Asp and γ320Asp that binds calcium (8, 9, 30). Alanine substitutions 
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for these carboxylate moieties have been shown to impair calcium binding, fibrin 
polymerization,   and    fibrinogen-mediated   platelet  aggregation  (31).  Another  negatively  
charged surface adjacent to hole “a” is loop γ291-301 which contains γ298Asp and γ301Asp 
that also bind calcium. Studies of recombinant fibrinogen γD298,301A suggested that 
changes in loop γ294-301 could possibly alter the integrity of hole “a” (32). Inspection of 
hole “a” itself showed that γ330Asp and γ364Asp are the two residues that contribute mostly 
to the local negative charge in the cavity so that in the γD364A structure, the negative charge 
distribution inside the cavity is substantially decreased. 
 
     2.3.4 Plasmin Protection Assay. To assess binding of both calcium and GPRP in γ364Asp 
variants, we performed plasmin protection assays. In this assay, the addition of GPRP or 
calcium to the reaction limits the plasmin proteolysis of fibrinogen to fragment D1. In the 
presence of EDTA or in the absence of GPRP, fragment D1 is further cleaved to the smaller 
fragments D2 and D3. This assay also enabled us to determine whether GPRP binding 
observed in the crystal structure of γD364A also occurs in solution. As shown in Figure 2.6, 
essentially only fragment D1 was seen in normal and variant fibrinogens at 5 mM CaCl2 
while in the presence of 5 mM EDTA, only the smaller fragments D2 and D3 were evident. 
Thus, with normal and variant fibrinogen, calcium protected fragment D1 from further 
cleavage to D2 and D3 suggesting that calcium binding is not altered in these variants. In the 
presence of 4 mM or 20 mM GPRP, only the normal fibrinogen was completely protected 
from plasmin as evident from the presence of only fragment D1. At both 4 mM and 20 mM 
GPRP, the γD364A digests contained fragments D2 and D3 and a significant level of D1, 
demonstrating partial plasmin protection. Our crystal structure showed GPRP binding to hole 
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“a” in γD364A, thus, we expected to see complete protection from plasmin digestion. 
Because γD364A showed partial degradation, we concluded that γD364A weakly binds 
GPRP. In contrast, fragments D2 and D3 were the only products of plasmin digestion with 
γD364H and γD364V fibrinogens, indicating complete loss of protection. We concluded that 
the extensive degradation of γD364H and γD364V indicates severely impaired holes “a” that 
are incapable of binding GPRP. 
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Figure 2.5  Charge distribution comparison of hole “a” in normal and γD364A. The 
structures show patches of surface accessible negative electrostatic potential (shown in red) 
that surround hole “a”. These areas consist of loops γ316-324 and γ291-301 that contain 
calcium binding sites. Inside the cavity of hole “a” are residues γ364Asp and γ330Asp that 
contribute to the local negative charge. Note the diminished negative charge in hole “a” of 
γD364A. 
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Figure 2.6. Plasmin protection assay. Normal recombinant or variant fibrinogens (0.25 
mg/mL) in HBS buffer containing 5 mM CaCl2, 5 mM EDTA, 4 mM  or 20 mM GPRP 
(supplemented with 5 mM EDTA) were incubated with 4.8 μg/mL plasmin for 4 h at 37oC 
and the digests were analyzed on 7.5% SDS-PAGE. The fibrinogen degradation products are 
indicated on the left.  
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2.4 Discussion 
     Although the interactions between γ364Asp and GPRP have been shown in several 
crystallographic studies of fibrinogen, the impact of substitution at this site was not fully 
appreciated at the molecular level. Our structural data showed GPRP bound to hole “a” in 
γD364A despite loss of the ionic interaction between the carboxylate side chain of γ364Asp 
and the free amino group of the peptide. Partial protection from plasmin proteolysis suggests 
GPRP binds to hole “a” in γD364A, although probably more weakly compared to normal. In 
contrast, the lack of protection and extensive degradation by plasmin implies GPRP does not 
bind either γD364H or γD364V. The protection conferred by calcium suggests the global 
structure of γD364H and γD364V are not markedly different from normal. 
     Previous studies with reptilase, an enzyme that cleaves only FpA, revealed normal FpA 
release in all γ364Asp variants but polymerization was not evident by either turbidity or γ-γ 
dimer formation (12). These data indicate that these variants have incompetent holes “a” such 
that “A:a” interactions are not sufficient for polymerization. Moreover, laser tweezers 
experiments  showed “A:a” interactions were undetectable in both γD364A and γD364H 
(33). Based on these functional data, we expected structural studies would show altered hole 
“a” in γD364A. Thus, we were surprised to find that γD364A can support GPRP binding to 
hole “a”. The rfD-γD364A +GP structure showed that “A:a” interactions can occur. With 
both normal and γD364A fibrinogen capable of “A:a” interactions with only minor changes 
in hole “a” , one would wonder why γD364A function is so impaired compared to normal. 
Questions then arise: how does γ364Asp impact “A:a” interactions and how does the loss of 
this acidic residue affect polymerization?  
 39
     In the first three-dimensional structures showing the polymerization hole obtained from a 
30-kDa C-terminal γ-chain fragment with and without GPRP peptide, Yee, Pratt et al. (24, 
30) showed large areas of negatively charged residues in and around hole “a” that result to a 
large molecular dipole moment. This cluster of negative charges interacts with the positively 
charged GPRP. The authors suggested that electrostatic steering may be a significant 
component of the fibrin polymerization mechanism that guide the alignment of fibrin 
monomers (30). Hole “a” is surrounded by negatively charged loops that bind calcium and 
inside the cavity are two acidic residues γ330Asp and γ364Asp that give the hole a local 
negative charge. These residues may provide a local negative charge that attracts and 
facilitates binding of the positively charged knob “A” to hole “a”. It is known from the amino 
acid sequence of fibrinogen that the molecule has considerably more negative than positive 
charges, with much of the excess negative charges located at the central domain (34). 
Removal of the two FpAs reduces the negative charge on the central domain from -8 to -1 
but it is only after cleavage of FpB that the central domain actually assumes a net positive 
charge (3). It is reasonable to conclude then that the local negative charge on hole “a” 
reinforces electrostatic steering so that knobs “A” at the center of one molecule are able to 
find the holes at the terminal ends of another molecule during protofibril formation. The 
prolonged lag time during thrombin-catalyzed polymerization (12) suggests slow protofibril 
formation in γD364A and may be a consequence of the diminished electrostatic steering due 
to the loss of the acidic γ364Asp .  
     The fact that GPRP confers only partial and not full protection to γD364A from plasmin 
degradation suggests a lower knob-hole affinity and less stable binding compared to normal. 
The salt bridge between the γ364Asp carboxylate and the free amino group of the knob 
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strengthens “A:a” interactions and  loss of such an important ionic interaction may contribute 
to less stable “A:a” interactions in γD364A. Complete protection with calcium suggests that 
there are no global changes in the structures of γD364H and γD364V but the complete loss of 
protection with GPRP suggests these altered holes “a”  do not bind GPRP. Valine has a 
slightly bigger van der Waals volume (105 Å3) than aspartic acid (91 Å3) such that contact 
between the aliphatic side chain and the positively-charged amino group of the knob is 
unfavorable. In the event of knob “A” binding, valine could undergo a rotameric switch but 
unlike aspartic acid or alanine, branching at the β-carbon limits its conformational freedom. 
These steric effects would highly destabilize “A:a” interactions in γD364V, in addition to the 
loss of the important electrostatic steering mediated by γ364Asp. For γD364H, the polar and 
bulky histidine (118 Å3) may introduce rearrangements in neighboring residues. This may 
alter the shape and volume such that there is no reasonable polymerization hole present in 
γD364H. In addition to the loss of the electrostatic force that attracts and directs the knob to 
the hole, the substantial rearrangements in γD364H may preclude “A:a” interactions in this 
variant.  
     In summary, our biochemical and structural data showed that γ364Asp may not be 
required for knob “A” binding to hole “a” per se but substitution at this position alters the 
electrostatic properties of hole “a” that may be critical for normal fibrin polymerization.  
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CHAPTER 3 
 
 
 
FIBRINOGEN VARIANT BβD432A HAS NORMAL POLYMERIZATION 
BUT DOES NOT BIND KNOB “B” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Submitted for publication to Blood on September 19, 2008. Minor revisions invited as of 
press time.  
 
3.1 Introduction 
     The fibrinogen molecule consists of three pairs of non-identical polypeptide chains, Aα, 
Bβ and γ, folded into three distinct structural regions, two distal D regions linked by coiled-
coil connectors to one central E region forming a trinodular structure (1). Each D region 
contains polymerization holes “a” and “b” located in the C-terminus of the γ and Bβ chains, 
respectively. The central E region contains two sets of polymerization knobs “A” and “B” 
that are cryptic in fibrinogen but become exposed in fibrin after thrombin cleaves 
fibrinopeptide A (FpA) and fibrinopeptide B (FpB) from the N-terminus of the Aα and Bβ 
chains, respectively (1, 2). The exposed knob “A” binds to hole “a” of another fibrin 
molecule forming “A:a” interactions that lead to a double-stranded protofibril with a half-
staggered overlap between molecules in different strands. Cleavage of FpB occurs primarily 
during protofibril growth, leading to the binding of knob “B” to hole “b” forming “B:b” 
interactions (1). 
     The location of the binding holes and possible models for knob-hole interactions are 
known from X-ray crystallographic studies using two synthetic peptide analogs of knobs “A” 
and “B”. When fibrinogen fragment D and double-D are crystallized in the presence of both 
peptide analogs, the knob “A” peptide mimic, Gly-Pro-Arg-Pro-amide (GPRP), forms H-
bond interactions with residues γ364Asp, γ330Asp, γ329Gln and γ340His found in hole “a” 
(3-5). In the same manner, the knob “B” peptide mimic, Gly-His-Arg-Pro-amide (GHRP) 
interacts with residues Bβ397Glu, Bβ398Asp and Bβ432Asp in hole “b” (3, 5, 6). 
     The functional role of “A:a” interactions were demonstrated in several studies with 
reported dysfibrinogenemias (7, 8), as well as studies with γ364Asp variant fibrinogens (9). 
While the importance of “A:a” interactions have been well documented, the role of “B:b” 
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interactions is still unclear. Previously published data on BβD432A fibrinogen, a variant with 
mutation in hole “b”, showed normal polymerization (10). Without structural data for 
BβD432A, it is reasonable to anticipate that BβAsp432 may not be critical in binding knob 
“B” and that there may be alternative and new sets of interactions in BβD432A that would 
still allow “B:b” interactions to occur. We also based this hypothesis on recent studies with 
γD364A variant fibrinogen (11). The two aspartate residues, BβAsp432  in hole “b” and 
γAsp364  in hole “a” form ionic interactions with the positively-charged free amino-terminus 
of their corresponding knob and are located at equivalent positions in the β- and γ-chain 
polymerization holes, respectively (3, 5).  While γD364A showed severely impaired function, 
structural data on this variant surprisingly showed that hole “a” binds knob “A” peptide 
mimic, GPRP suggesting that the residue γAsp364 per se is not critical for “A:a” interactions 
(11). In contrast to γD364A, we now report that BβD432A does not bind knob “B” peptide 
mimic, GHRP and that the residue BβAsp432 is critical for “B:b” interactions. This 
surprising finding led us to further examine the polymerization of BβD432A and re-evaluate 
the importance of hole “b” and “B:b” interactions. Our biochemical data suggest that 
BβD432A, indeed, has normal polymerization despite having impaired hole “b”. In 
summary, our findings suggest that hole “b” may have very little influence on 
polymerization; that other events such as FpB release is more critical to polymerization, 
rather than the actual “B:b” knob-hole binding.   
 
3.2 Experimental Methods   
      3.2.1 Reagents. All chemicals were of reagent grade and were purchased from Sigma-
Aldrich (St. Louis, MO), unless specified otherwise. The peptide GHRP was synthesized by 
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the Protein Chemistry Laboratory at the University of North Carolina at Chapel Hill (Chapel 
Hill, NC). Cell culture media with normal recombinant fibrinogen was obtained from the 
National Cell Culture Center (Minneapolis, MN). Monoclonal IF-1 antibody was purchased 
from Kamiya Biomedical (Seattle, WA). 
 
     3.2.2 Expression and Purification of Recombinant Fibrinogen BβD432A. Normal and 
variant BβD432A fibrinogens were synthesized in CHO cells as described previously (10). 
Large scale protein expression was carried out in serum-free medium in roller bottles. Media 
containing secreted fibrinogen were harvested periodically. After addition of protease 
inhibitors, the media were stored at -20oC (12). 
     Recombinant fibrinogen was purified as described (13). Briefly, fibrinogen was 
precipitated from the media with ammonium sulfate in the presence of a cocktail of protease 
inhibitors. The precipitate was resuspended in buffer containing 10 mM CaCl2 and applied to 
a Sepharose 4B column coupled with the fibrinogen specific monoclonal antibody, IF-1. 
Fibrinogen was eluted from the column with buffer containing 5 mM EDTA; dialyzed 
against HEPES Buffered Saline (HBS) (20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, adjusted to pH 7.4 by NaOH, 150 mM NaCl) and 1 mM CaCl2 
for one exchange and then extensively dialyzed against HBS; and stored at -80oC. The 
integrity of the polypeptide chains and purity of the recombinant protein were analyzed by 
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and 
nonreducing condition following the method of Laemmli (14). 
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     3.2.3 Preparation and Purification of Fragment D. Fragment D was prepared from 
BβD432A by controlled trypsin digestion, according to the method used for normal 
recombinant fibrinogen (5). Briefly, CaCl2 (final concentration of 20 mM) was added to 10 
mg of BβD432A fibrinogen in HBS and digestion was initiated by adding 100 μL of 
immobilized TPCK Trypsin (Pierce Biotechnology Inc., Rockford, IL). The reaction was 
allowed to proceed over a period of days until SDS-PAGE revealed essentially two bands 
that correspond to the molecular weights of fragments D and E.  Digestion was stopped by 
removing the trypsin beads with centrifugation at 3000 rpm (Sorvall RC-3) for 10 mins.  
     Fragment D was purified by peptide affinity chromatography based on previously 
described methods (15). Briefly, the digest was loaded onto a polymeric resin covalently 
linked to the peptide GPRPAA. Fragment D was eluted using 50 mM sodium acetate (pH 
5.3) and 1 M NaBr. Purified fragment D was dialyzed against 50 mM Tris-HCl, pH 7.4, 
concentrated a 100-fold with a centrifugal filter device (50 kDa MW cutoff, Millipore Corp., 
Billerica, MA) and stored at 4oC.  
 
    3.2.4 Crystallization of Fragment D from BβD432A. Purified BβD432A fragment D was 
co-crystallized with GHRP by sitting-drop diffusion at 4oC similar to methods previously 
described for normal fragment D crystallization (3, 5). Crystals were grown from drops 
containing 5 μL of  BβD432A fragment D initially at 10 mg/mL in 50 mM Tris-HCl, pH 7.4 
and GHRP at 4 mM mixed with an equal volume of well solution containing 50 mM Tris-
HCl, pH 8.5, 2 mM NaN3, 12.5 mM CaCl2 and 11-14% (w/v) PEG 3350. Single crystals 
appeared in days, following streak seeding with crystals of normal recombinant fragment D. 
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     3.2.5 X-ray Diffraction Data Collection and Structure Determination. Data collection for 
crystals of BβD432A fibrinogen fragment D (rfD-BβD432A+GH) was carried out at 100 K 
using SER-CAT beamline 22-ID at the Advanced Photon Source. A single crystal was 
cryoprotected in loop containing the cystallant solution plus 20% glycerol and 4 mM 
GHRPam then flash-frozen in liquid nitrogen. Diffraction data were processed with DENZO 
and ScalePack (16). 
     The structure of rfD-BβD432A+GH was solved by molecular replacement using MolRep 
(17) in CCP4i (18) with one molecule of the normal recombinant fragment D structure, rfD 
(PDB code: 1LT9) as the search model. The solution gave a correlation coefficient and R-
factor of 53.0% and 45.8%, respectively. The resulting model was refined using CNS (19) 
reserving 5% of the reflections for the calculation of the free R-factor. After one round of 
refinement, the model was improved by manual fitting in the program O (20) using sigmaA-
weighted |2Fo - Fc| and |Fo - Fc| electron density maps (21). Several cycles of least square 
minimization, simulated annealing and individual temperature factor refinement applying 
weak non-crystallographic restraints in the first cycles were done before water molecules 
were added to complete the model. Furthermore, cis-peptide bonds were added at positions 
Bβ407 and γ339. After all these refinement steps, the Rcrystal and Rfree converged to the values 
reported in Table 3.1.   
 
     3.2.6 Thrombin-Catalyzed Polymerization. Thrombin-catalyzed polymerization of 
BβD432A was monitored as the turbidity changes at 350 nm using SpectraMax PC microtiter 
plate reader (Molecular Devices, Sunnyvale, CA) essentially as described (22). Briefly, 10 
μL of 1 U/mL thrombin was added to reaction wells containing 90 μL of 0.22 mg/mL 
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fibrinogen in HBS with no added calcium and with CaCl2 at final concentrations of 10 μM, 1 
mM and 10 mM. Polymerization was monitored for 60 min at room temperature. Three 
distinct parameters were analyzed: (1) the time it takes for the absorbance to rise above zero 
(lag time); (2) the portion of the curve with the steepest slope after the absorbance starts to 
rise (Vmax); and (3) the final maximum absorbance (ODmax). 
      
     3.2.7 Scanning Electron Microscopy (SEM). Fibrin clot and specimen preparations were 
based on a previously described method with some modifications (22). For each 
polymerization condition, SEM was performed on two clots each with two separate 
microscopy preparations for normal and BβD432A. Clots were polymerized in microtiter 
plate wells at 0.5 mg/mL fibrinogen and 0.4 U/mL of batroxobin or thrombin in HBS and 1 
mM CaCl2 for 2 hours. The clots were then fixed in 2% glutaraldehyde overnight, rinsed 
three times with HBS then dehydrated with a series of ethanol solutions (20-100%). The 
samples were then critical-point-dried in a Balzers CPD020, mounted, sputter-coated with 
approximately 20 nm gold-palladium, and viewed on a Zeiss Supra 25 FESEM (Carl Zeiss 
MicroImaging,  Inc.,  Thornwood, NY).  All  images  were  taken at 50,200 x  with a  3.0 mm  
working distance and 4.99 kV accelerating voltage. Fiber diameters were calculated using the 
measurement tool in Photoshop (Adobe Systems, San Jose, CA).  
 
     3.2.8 Factor XIIIa-catalyzed crosslinking of fibrin. Factor XIII (Enzyme Research 
Laboratories, South Bend, IN, USA) was activated with human α-thrombin for 60 min at 
37°C in HBS with 5 mM CaCl2. To examine the crosslinking of fibrin, fibrinogen (5 μg) in 
HBS and 5 mM CaCl2, was incubated at 37 °C with a mixture of FXIIIa (3.3 U/mL) and 
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human α-thrombin (0.07 U/mL). To examine the crosslinking of batroxobin-catalyzed fibrin, 
hirudin (10 U/mL) was added to the thrombin-activated FXIIIa prior to incubation with 
fibrinogen and batroxobin (0.08 U/mL). The reactions were stopped by the addition of SDS-
PAGE sample buffer with 2-mercaptoethanol followed by heating at 100 °C. Sample 
components were separated by 8% SDS-PAGE and stained with Coomassie Brilliant Blue R-
250. Densitometric analyses of stained gels were performed using the gel analysis tools in 
ImageJ (NIH, Bethesda, MD) and γ-γ/Bβ ratios were calculated. 
 
     3.2.9  Statistical analysis. The statistical significance of differences between normal 
control and variant fibrinogen was determined using unpaired t-tests. A difference was 
considered significant when the P-value was <0.05. 
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Table 3.1:       Crystallographic Data and Refinement Statistics a 
Data Statistics 
     resolution (Å) 50.0 - 2.15 
     space group P212121 
     cell constants (Å) a = 54.5 
b = 146.6 
c = 229.0 
     molecules/asymmetric unit 2 
     total observations 877794 
     unique reflections 139737 
     mean redundancy 6.7 
     Rsymb (%) 6.4 (33.1) 
     completeness (%) 94.8 (83.4) 
     mean I/σ 29.5 (4.2) 
Refinement Statistics 
     Rcrystb (%) 23.8 
     Rfree c (%) 26.2 
     average B factor (Å 2) 41.8 
     number of model atoms  10676 
     number of solvent sites 260 
RMS deviations from ideals  
     bond length (Å) 0.006 
     bond angles (deg) 1.24 
a The atomic coordinates have been deposited in the Protein Data Bank 
(www.rcsb.org) under the access code 3E1I (rfD-BβD432A+GH). 
 b Rsym = Σ|I - 〈I〉|, where I is the observed intensity and 〈I〉 is the 
average intensity of multiple symmetry-related observations of that 
reflection. b Rcryst = Σ(|Fobs|- |Fcalc|)/Σ|Fobs|, where Fobs  and Fcalc are the 
observed and calculated structure factors, respectively. c Rfree is the R-
factor based on the 5% of the data withheld from structural refinement. 
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3.3 Results 
     3.3.1 Structure of rfD-BβD432A+GH. To understand the molecular basis for the normal 
turbidity of BβD432A, we determined the crystal structure of fragment D from this variant, 
crystallized in the presence of GHRP. We obtained high quality diffraction data and were 
able to solve the structure at 2.15 Å. A total of 643 amino acid residues in one fragment D 
molecule (α134-190, β161-458 and γ105-392) can be elucidated clearly from the electron 
density. The substitution of the Asp to Ala at position Bβ432 was evident. Alignment of the 
Cα-atoms in normal and BβD432A fragment D showed excellent agreement with RMSD of 
0.75 Å, demonstrating that the global structure of rfD-BβD432A+GH was not changed by 
the alanine substitution. 
     Surprisingly, the structure of rfD-BβD432A+GH showed that GHRP is not bound to hole 
“b”. As shown in Figure 3.1, there was no electron density in |2Fo - Fc| and |Fo - Fc| maps for 
peptide in hole “b”. Moreover, the structure of hole “b” in rfD-BβD432A+GH is reminiscent 
of the structure of normal recombinant fragment D in the absence of peptides (rfD). We did 
see GHRP bound in hole “a” (Figure 3.2). Thus, the rfD-BβD432A+GH structure resembled 
that of rfD-BβD398A+GH, another variant with mutation in hole “b”, BβD398A, crystallized 
in the presence of GHRP. The rfD-BβD398A+GH structure showed that GHRP was not 
bound to hole “b” but was bound to hole “a” in the γ-chain forming non-canonical “B:a” 
interactions (10). As with the rfD-BβD398A+GH structure, comparison of the two molecules 
in the asymmetric unit of rfD-BβD432A+GH showed two different structures for two “B:a” 
interactions with calcium present in the γ2 site in only one of the molecules (Figure 3.2). The 
γ2 calcium is located in the γ294-301 loop, which is in close proximity to hole “a”. This 
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calcium binding site has also been observed in structures of normal fragment D and its 
crosslinked form (23), as well as in recombinant rfD-BβD398A+GH (10), when the proteins 
were crystallized in the presence of GHRP alone. Studies with recombinant fibrinogen 
γD298,301A showed modest impairment in polymerization suggesting that γ2 does not 
significantly modulate polymerization (24). 
      
     3.3.2 Calcium Binding in Crystal Structure. It is well known from crystal structures that 
fragment D has a high-affinity calcium-binding site in the γ chain, designated as γ1. Another 
calcium binding site which is analogous to γ1, is located at an equivalent position in the β-
chain adjacent to hole “b”, designated as β1. Both the γ1 and β1 calcium binding sites are 
present in the rfD-BβD432A+GH structure (Figure 3.3A). An additional calcium binding 
site, designated as β2, which is located near the junction of the βC-module and the coiled-
coil region, is also seen in rfD-BβD432A+GH. This calcium ion anchors the βC-module to 
the coiled-coil region and is coordinated by the side chains of BβAsp398, BβAsp261, 
γGlu132 and the backbone carbonyl oxygen of BβGly263 (3, 5). Binding of peptide to hole 
“b”, as observed in the structures of normal fragment D crystallized in the presence of 
peptides, rfD+BOTH (Figure 3.3B), causes BβGlu397 and BβAsp398 to flip towards 
BβAsp432 to interact with the peptide (5, 23). Because BβAsp398 is part of the β2 calcium 
coordination, movement of BβGlu397 and BβAsp398 causes the disruption of the β2 site 
upon peptide binding. In rfD-BβD432A+GH, peptide binding to hole “b” is lost, hence, the 
calcium is present in the β2 site. 
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Figure 3.1 Comparison of polymerization hole “b” in (A) rfD-BβD432A+GH and (B) 
normal rfD+BOTH. For both structures, the difference electron density |Fo - Fc| is 
contoured at 3.0σ and is shown in green. The |2Fo - Fc|  electron density maps are contoured 
at 1.0σ shown in gray. Clear positive difference electron density for GHRP is evident in hole 
“b” of normal rfD+BOTH and is absent in the rfD-BβD432A+GH structure. This suggests 
that BβD432A has an impaired hole “b” and does not bind the peptide. Note the positions of 
BβGlu397 and BβAsp398. In normal rfD+BOTH, both residues flip towards hole “b” to 
interact with GHRP. In rfD-BβD432A+GH, these residues are nowhere near hole “b”. 
Figures were displayed using Pymol (Delano Scientific, CA). 
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Figure 3.2 Electron density corresponding to GHRP in hole “a” of the two molecules in 
the asymmetric unit of rfD-BβD432A+GH. The |Fo - Fc| electron density around GHRP 
(shown as green sticks) is contoured at 3.0σ. The two calcium binding sites γ1 and γ2 are 
shown as orange spheres. Note that the calcium in γ2 site is absent in the other molecule of 
the asymmetric unit. Figures were displayed using Pymol (Delano Scientific, CA). 
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Figure 3.3 Structures of (A) rfD-BβD432A+GH and (B) normal rfD+BOTH showing 
the conformational change when peptide is bound to hole “b”. Residues involved in β2 
calcium and peptide binding are shown as pink sticks. Note the conformational change in 
residues Bβ397Glu and Bβ398Asp when peptide (shown as blue sticks) is bound to hole “b”, 
as in the case of normal.  In the rfD-BβD432A+GH structure, hole “b” does not bind the 
peptide so that Bβ398Asp, together with γ132Glu coordinates the β2 calcium (shown as 
orange sphere) which tethers the βC-module to the coiled coil. Figures were displayed using 
Pymol (Delano Scientific, CA). 
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    3.3.3 Thrombin-Catalyzed Polymerization of BβD432A. Because the loss of “B:b” 
interactions appeared inconsistent with our prior findings, we re-evaluated the 
polymerization of this variant. Thrombin-catalyzed polymerization experiments were 
performed as described before (10) and carried out at three calcium concentrations: 10 μM 
CaCl2, 1 mM CaCl2 and 10 mM CaCl2. Consistent with previous data, the variant BβD432A 
was indistinguishable from normal fibrinogen for essentially all parameters examined (Table 
3.2).  All polymerization parameters (lag time, Vmax and ODmax) were not significantly 
different for BβD432A and normal with the exception of the lag time at 10 mM CaCl2 in 
which BβD432A had a longer lag time (p = 0.01). 
     To confirm that the final turbidity was indicative of fiber thickness and to quantitate the 
differences in fiber thickness, we examined thrombin- and batroxobin-catalyzed fibrin clots 
using scanning electron microscopy. Consistent with our turbidity data, clots formed from 
BβD432A have similar fiber diameters as those formed from normal fibrinogen (Figure 3.4). 
For the clots formed using thrombin, we found the average fiber diameter for BβD432A was 
84 ± 18 nm which was essentially similar to normal with an average fiber diameter of 83 ± 
18 nm (p = 0.8). The batroxobin-derived clots for BβD432A had fiber diameter of 68 ± 13 
nm which was comparable to those of normal with average fiber diameter of 66 ± 15 nm (p = 
0.7). However, batroxobin-derived clots for either BβD432A or normal had significantly 
thinner fiber diameter compared to the thrombin-derived clots (p = 0.03 for BβD432A and p 
= 0.04 for normal) suggesting that FpB cleavage modulates fiber diameter. 
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    Table 3.2 Polymerization Parameters for Normal and BβD432A Fibrinogena 
 Lag Time 
(s) 
Vmax 
( x 10-4 s-1) 
ODmax 
at 350 nmb 
Normal 
10 μM CaCl2 196 ± 5 0.92 ± 0.1 0.15 ± 0.01 
1 mM CaCl2 169 ± 23 1.3 ± 0.3 0.19 ± 0.01 
10 mM CaCl2 133 ± 19 1.8 ± 0.5 0.20 ± 0.06 
BβD432A 
10 μM CaCl2 217 ± 52 1.1 ± 0.3 0.17 ± 0.02 
1 mM CaCl2 159 ± 29 1.3 ± 0.5 0.19 ± 0.03 
10 mM CaCl2 278 ± 39c 1.1 ± 0.5 0.20 ± 0.03 
a N = 3 for each value. b Final absorbance was determined as the absorbance at the 60 min time point of 
the polymerization reaction. c Denotes values found to be statistically different from normal fibrinogen 
determined by unpaired t-test. 
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Figure 3.4 Scanning electron micrographs of fibrin clots. Fibrinogen at 0.5 mg/mL was 
incubated with 0.4 U/mL thrombin (A: normal, B: BβD432A) for 2 h at 37oC in HBS with 1 
mM CaCl2. Images were recorded at 50,200 x magnification. The black bar scale represents 
200 nm. 
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     3.3.4 FXIIIa-catalyzed crosslinking. In recent studies, we concluded that “B:b” 
interactions promote protofibril assembly (9, 25, 26). FXIIIa-catalyzed γ-γ dimers form early 
in polymerization, likely as soon as protofibrils are present (27). We therefore analyzed the 
kinetics of γ-γ dimer formation since this could reflect subtle differences in protofibril 
formation between normal and BβD432A. In thrombin-catalyzed FXIIIa-crosslinking, both 
normal (Figure 3.5A) and BβD432A (Figure 3.5B) formed γ-γ dimer bands that were weakly 
evident after 2 min and increased in intensity with longer incubation times (Figure 3.5C). We 
also performed experiments in the presence of FXIIIa and batroxobin. Similar to thrombin-
catalyzed crosslinking, the γ-γ dimer bands were weakly evident after 2 min in both normal 
(Figure 3.5D) and BβD432A (Figure 3.5E) which increased in intensity with longer 
incubation (Figure 3.5F).  These data indicate that protofibril formation was not delayed for 
BβD432A, suggesting that protofibril formation in BβD432A is not markedly different from 
normal. 
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 Figure 3.5 FXIIIa-crosslinking of BβD432A and normal recombinant fibrinogen. 
Crosslinking was examined by 8% SDS-PAGE under reducing conditions. Fibrinogen (5 μg) 
was incubated with either FXIIIa and thrombin at final concentrations of 3.3 U/mL and 0.07 
U/mL, respectively (A: normal, B: BβD432A) or FXIIIa and batroxobin at final 
concentrations of 3.3 U/mL and 0.08 U/mL, respectively (D: normal, E: BβD432A). The 
samples were incubated for 0 min (lane 1), 2 min (lane 2), 5 min (lane 3), 10 min (lane 4), 20 
min (lane 5), 40 min (lane 6), 1h (lane (7) and 2 h (lane 8). Data was analyzed by 
determining the ratio of γ-γ dimers to Bβ chain by densitometry and are plotted thrombin (C: 
-■- normal, -□- BβD432A) and batroxobin (F: -●- normal, -○- BβD432A). 
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3.4 Discussion 
     Our structural data showed GHRP does not bind to hole “b” in BβD432A.  Hence, the 
variant lacks “B:b” interactions. Our biochemical data, which corroborate and extend 
previous studies, showed polymerization, fiber diameter and FXIIIa crosslinking of 
BβD432A were indistinguishable from normal. These findings are remarkable because they 
show that formation of crosslinked clots is normal even in the absence of “B:b” interactions. 
This then raises the question: Do “B:b” interactions actually occur in fibrin; and if they do, 
are they critical for fibrin clot formation?   
     Thirty years ago, Blomback et al.  (28) showed that fibers obtained from reptilase, which 
cleaves predominantly FpA, have lower mass-to-length ratio than those derived from 
thrombin. They then proposed a two-step sequence of events in fibrin polymerization where 
protofibril formation mediated by “A:a” interactions is followed by lateral aggregation of the 
protofibrils through “B:b” interactions. Subsequent studies by Weisel and Hantgan et al.  (29, 
30) showed the extent of lateral aggregation was greater for fibers with cleavage of both 
fibrinopeptides; the addition of thrombin after activation with reptilase, at a time when 
protofibrils have formed, caused rapid fiber formation. These studies demonstrated that the 
release of FpB, exposing knob “B”, has a marked impact, supporting the idea that “B:b” 
interactions are important in lateral aggregation.   
     Nevertheless, several observations, including these studies, suggest otherwise. Even 
though the snake venom enzymes cleave only FpA, they still produce normal-looking fibers 
albeit thinner in diameter.  Thus, protofibrils are formed and these protofibrils are capable of 
lateral aggregation even in the absence of “B:b” interactions (31). The knob “A” peptide 
mimic, GPRP, has been shown to inhibit polymerization (32) whereas knob “B” peptide 
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mimic GHRP does not (33). In fact, GHRP and other knob “B” peptide analogs enhance 
turbidity during thrombin-catalyzed polymerization (34).   Thus, “B:b” interactions are not 
essential for lateral aggregation. 
     More recent studies proposed a role for “B:b” interactions in protofibril formation. These 
studies examined polymerization of single-substituted recombinant fibrinogens, γD318A and 
γD320A, which have changes in the high affinity high affinity calcium binding site (25), and 
γD364V, γD364H and γD364A, which have changes in hole “a” (9). These variants did not 
polymerize with batroxobin indicating complete loss of “A:a” interactions. They did, 
however, polymerize with thrombin although with markedly delayed kinetics. This thrombin-
induced polymer formation was inhibited by GHRP suggesting that “B:b” interactions 
support protofibril formation, at least in the absence of normal “A:a” interactions.  With 
normal “A:a” interactions, as seen with reptilase, the subsequent addition of thrombin might 
stabilize protofibrils, and consequently enhance fiber formation. 
     In contrast to the previous reports, our results with BβD432A suggest “B:b” interactions 
are not critical for  normal polymerization.  To reconcile these differences, we propose that 
the loss of FpB, rather than the gain of “B:b” interactions, influences polymerization. 
Because FpB is electronegative, diminished electrostatic repulsion between associating fibrin 
molecules can be surmised after cleavage of FpB. Although the removal of the two FpAs 
reduces the negative charge, it is only after FpB release that the central domain actually 
assumes a net positive charge to favor association with the negatively-charged D nodules. 
Aside from electrostatic factors, FpB also modulates fibrinogen structure through 
intramolecular interactions with the αC domains (35).  Following FpB release, the αC 
domains dissociate so they are free to form intermolecular associations enhancing lateral 
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aggregation (35, 36). These findings suggest the role of FpB in modulating polymerization, 
while our data indicate that actual occupancy of hole “b” is not critical to fibrin clot 
formation.  
     While hole “b” may only have very little influence on polymerization, recent data indicate 
that “B:b” interactions play a more important role in fibrinolysis (34). Previous studies have 
suggested that a consequence of “B:b” interactions may be a global conformational change 
where the β2 calcium anchor is disrupted and the βC-module disengages from the coiled coil 
(5). The resulting conformation may lead to increased accessibility to a tPA (or plasminogen) 
binding site at α148-160 (Figure 3.3B) when binding of the tethered knob to hole “b” locks 
and prevents the βC-module from retreating back towards the coiled-coil region (37). Indeed, 
addition of free, untethered knob “B” peptide mimics that can compete with the authentic 
tethered knob resulted to delay in fibrinolysis. Our data from our experiments using 
BβD432A and the peptide AHRPY, which exclusively binds to hole “b”, are consistent with 
this observation (unpublished findings).  
     In summary, we have shown that Bβ432Asp is critical for peptide binding. However, the 
normal polymerization of BβD432A despite absence of “B:b” interactions suggests that 
occupancy of hole “b” may have little impact on polymerization. It may be that FpB release 
and electrostatic factors are more critical than actual “B:b” knob-hole binding.  
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CHAPTER 4 
 
 
 
 
FIBRINOGEN VARIANT γN308K IMPAIRS FIBRIN ALIGNMENT, KNOB-HOLE 
INTERACTIONS AND CALCIUM BINDING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1 Introduction 
     Fibrinogen is a 340-kDa plasma glycoprotein composed of six polypeptide chains, (Aα, 
Bβ, γ)2, folded into three distinct structural regions, two distal D regions linked by coiled-coil 
connectors to one central E region forming a trinodular structure (1).  Each D region contains 
several calcium-binding sites and polymerization holes “a” and “b” located in the C-terminus 
of the γ and Bβ chains, respectively. The central E region contains two sets of polymerization 
knobs “A” and “B” that are cryptic in fibrinogen but becomes exposed in fibrin after 
thrombin cleaves fibrinopeptides A and B from the N-terminus of the Aα and Bβ chains, 
respectively (1). The exposed knob “A”, which starts with the sequence Gly-Pro-Arg-, binds 
to hole “a” of another fibrin molecule forming “A:a” interactions that lead to a double-
stranded protofibril with a half-staggered overlap between molecules in different strands. 
Cleavage of FpB occurs primarily during protofibril growth, leading to the binding of knob 
“B”, which starts with the sequence Gly-His-Arg- to hole “b” forming “B:b” interactions. 
During the end-to-end alignment of fibrin monomers, surface-exposed regions of the γ-chains 
of two adjacent molecules abut each other and form the D:D interface (1, 2). 
     High resolution structures have identified the location of the binding holes and models 
were identified for knob-hole interactions as well as residues that are likely to form the D:D 
interface between fibrin units. This interface forms an asymmetric set of interactions between 
identical and adjacent fibrin units. The structure shows only a few potential hydrogen bonds 
and no obvious salt links (2). Several dysfibrinogens involving residues in the D:D interface 
including γ308Asn and γ275Arg have been reported in patients predisposed to thrombosis or 
bleeding (3). The γN308K mutation, for example, was identified in fibrinogens Kyoto I, 
Bicetre II and Matsumoto II. Fibrinogen Kyoto I was isolated from an asymptomatic, 
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hypofibrinogenemic patient who had a family history of both thrombotic and bleeding 
problems (4). Fibrinogen Bicetre II was found in a patient who suffered pulmonary embolism 
while Fibrinogen Matsumoto II was isolated from a patient with severe history of bleeding 
(5, 6).  
     Biochemical analysis of recombinant fibrinogens γN308K, γN308I and γN308A showed 
all three variants had impaired polymerization in the absence of added calcium (7). At 0.1 
mM calcium, polymerization of both γN308I and γN308A was only slightly impaired while 
γN308K was still markedly different from normal even at 5 mM calcium. This unusual 
insensitivity to calcium was also apparent in the kinetics of thrombin-catalyzed FpB release, 
such that the delayed FpB release correlated with impaired polymerization. FXIIIa-catalyzed  
covalent γ-γ dimer formation was also significantly delayed in γN308K. These studies 
suggest that a critical aspect of polymerization in conjunction with calcium binding is 
disrupted in γN308K (7). However, calcium binding studies with γN308K fragment D 
derived from a patient plasma showed essentially identical binding when compared to normal 
(8). Although γ308Asn is located at the D:D interface, it is also near polymerization hole “a” 
and the high affinity calcium binding site, γ1. Whether or not γN308K substitution impacts 
either “A:a” interactions or  γ1 calcium binding remains unclear. 
     In this study, we examined the structural basis for the functional impairment of γN308K. 
We characterized binding of calcium and GPRP to γN308K using proteolysis protection 
assay.   We extended previous turbidity studies by examining the clot structure of the variant 
compared to normal. We also crystallized fragment D from γN308K in the presence of the 
synthetic peptide GPRP and solved the 3.0 Å structure (rfD-γN308K+GP). Our biochemical 
and structural data suggest γ308Asn is critical not only for charge complementarities of the 
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D:D interface during end-to-end association of fibrin molecules but is also for the structural 
integrity of loops that influence “A:a” knob-hole interactions and calcium binding.  
 
4.2 Experimental Methods 
      4.2.1  Reagents. All chemicals were of reagent grade and were purchased from Sigma-
Aldrich (St. Louis, MO), unless specified otherwise. The peptide GPRP-amide was 
purchased from Bachem Americas, Inc. (Torrance, CA). Cell culture media with normal 
recombinant fibrinogen was obtained from the National Cell Culture Center (Minneapolis, 
MN). Monoclonal IF-1 antibody was purchased from Kamiya Biomedical (Seattle, WA). All 
molecular graphics were illustrated using PyMol (DeLano Scientific LLC, Palo Alto, CA).  
 
     4.2.2 Expression and Purification of Recombinant γN308K. Normal and variant 
fibrinogen γN308K were synthesized in CHO cells as described previously (7). Large scale 
protein expression was carried out in serum-free medium in roller bottles. Media containing 
secreted fibrinogen were harvested periodically. After addition of protease inhibitors, the 
media were stored at -20oC . 
     Recombinant fibrinogen was purified as described (9).  Briefly, fibrinogen was 
precipitated from the media with ammonium sulfate in the presence of a cocktail of protease 
inhibitors. The precipitate was resuspended in buffer containing 10 mM CaCl2 and applied to 
a Sepharose 4B column coupled with the fibrinogen specific monoclonal antibody, IF-1. 
Fibrinogen was eluted from the column with buffer containing 5 mM EDTA; dialyzed 
against HBS (20 mM HEPES, adjusted to pH 7.4 with NaOH, 150 mM NaCl) and 1 mM 
CaCl2 for one exchange and then extensively dialyzed against HBS; and stored at -80oC. The 
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integrity of the polypeptide chains and purity of the recombinant protein were analyzed by 
SDS-PAGE under reduced and nonreduced condition following the method of Laemmli (10). 
  
      4.2. Scanning Electron Microscopy (SEM). Fibrin clot and specimen preparations were 
based on previously described method with some modifications (11). For each 
polymerization condition, SEM was performed on two clots each with two separate 
microscopy preparations for normal and γN308K. Clots were polymerized in microtiter plate 
wells using 0.5 mg/mL fibrinogen and 0.4 U/mL of thrombin in 20 mM HEPES, pH 7.4, 150 
mM NaCl without added CaCl2 and with 1 mM CaCl2 for 4 h. The clots were then fixed in 
2% glutaraldehyde overnight, rinsed three times with HBS then dehydrated with a series of 
ethanol solutions (20-100%). The samples were then dried in a Samdri-795 semi automatic 
critical point dryer (Rockville, MD), mounted, sputter-coated with approximately 20 nm 
gold-palladium, and viewed on a Zeiss Supra 25 FESEM (Carl Zeiss MicroImaging, Inc., 
Thornwood, NY). Images were taken at high magnification (101,000x and low magnification 
(21,000x) with a 9.0 mm working distance and 5 kV accelerating voltage. Fiber diameters 
were measured from the high magnification images using the measurement tool in Photoshop 
(Adobe Systems, San Jose, CA).  
 
     4.2.4 Plasmin Protection Assay. To determine whether the lysine substitution altered the 
calcium-binding site or polymerization hole “a”, we assessed binding of both calcium and the 
peptide GPRP using plasmin protection assay. This  assay is adapted from previous studies 
with some modifications (12). To examine calcium binding of normal and γN308K, CaCl2 or 
EDTA (at 5 mM final concentration) was added to ~5 µg fibrinogen at 0.2 mg/mL in HBS 
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prior to addition of plasmin. To examine binding of GPRP, varying concentrations of the 
peptide (2μM, 20 μM, 0.1 mM, 0.5 mM, 1 mM, 5 mM and 20 mM, supplemented with 5 mM 
EDTA) were incubated with 5 μg of fibrinogen. Digestion was initiated by adding plasmin 
(Haematologic Technologies, Inc., Essex Junction, VT) to a final concentration of 4.8 μg/mL 
and incubated for 4 h at 37oC. The reactions were stopped by adding SDS-PAGE loading 
buffer and heating at 100oC for 5 min. The plasmin digests were analyzed by non-reducing 
(7.5% gels) SDS-PAGE. Similar procedure was followed using 10 μg of fibrinogen and 120 
μg/mL final plasmin concentration. The plasmin digests were then analyzed by reducing 
(12.5% gels) SDS-PAGE. 
   
     4.2.5 Preparation and Purification of Fragment D. Fragment D was prepared from 
γN308K by controlled trypsin digestion as described (13). Briefly, CaCl2 (final concentration 
of 20 mM) was added to 10 mg of γN308K in HBS and digestion was initiated by adding 100 
μL of immobilized TPCK Trypsin (Pierce Biotechnology Inc., Rockford, IL). The reaction 
proceeded over a period of days until SDS-PAGE revealed essentially two bands that 
correspond to the molecular weights of Fragments D and E.  Digestion was stopped by 
removing the trypsin beads with centrifugation at 3000 rpm (Sorvall RC-3) for 10 min.  
     Fragment D was purified by peptide affinity chromatography as described (14). Briefly, 
the digest was loaded onto a polymeric resin covalently linked to the peptide GPRPAA. 
Fragment D was eluted using 50 mM sodium acetate, pH 5.3 and 1 M NaBr. Purified 
fragment D was dialyzed against 50 mM Tris-HCl, pH 7.4, concentrated to about 30 mg/mL 
with a centrifugal filter device (50 kDa MW cutoff, Millipore Corp., Billerica, MA) and 
stored at 4oC.  
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     4.2.6 Crystallization of γN308K Fragment D. Purified γN308K fragment D was co-
crystallized with GPRP by sitting-drop diffusion at 4oC as described (2, 13, 14). Crystals 
were grown from drops containing 5 μL of  γN308K fragment D initially at 10 mg/mL in 50 
mM Tris pH 7.4 and GPRP at 5 mM mixed with an equal volume of well solution containing 
50 mM Tris-HCl, pH 8.5, 2 mM NaN3, 12.5 mM CaCl2 and 9% (w/v) PEG 3350. Single 
crystals appeared in days, following streak seeding with crystals of normal recombinant 
fragment D. 
      
     4.2.7 X-ray Diffraction Data Collection and Structure Determination. Data collection for 
crystals of γN308K fragment D co-crystallized with GPRP (rfD-γN308K+GP) was carried 
out at 100 K using beamline X29A at the National Synchrotron Light Source at Brookhaven 
National Laboratory. A single crystal was cryoprotected in loop containing the cystallant 
solution plus 20% glycerol and 4 mM GPRP and flash-frozen in liquid nitrogen. Initial 
screening revealed the crystal had a long c cell edge; hence, oscillation data were recorded at 
a crystal-to-detector distance of 350 mm to achieve adequate diffraction spot separation. The 
data were processed with DENZO and scaled in SCALEPACK (15). 
     The structure of rfD-γN308K+GP was solved by molecular replacement using Phaser 
(16). The native Patterson map showed a large non-origin peak suggesting the presence of a 
translational non-crystallographic symmetry (NCS) in the structure. Thus, the strategy for 
molecular replacement involved using a search model consisting of two molecules of the 
normal recombinant fragment D (PDB code: 1LT9) separated by the NCS translation. The 
solution gave a high Z-score for each rotation and translation function without any clashes in 
the packing. The resulting model was refined using Refmac 5, reserving 5% of the reflections 
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for the calculation of the free R-factor. After one round of refinement, the model was 
improved by manual fitting with the program Coot (17) using sigmaA-weighted |2Fo - Fc| 
and |Fo - Fc| electron density maps (18). Water molecules and cis-peptide bonds were added 
at positions Bβ407 and γ339 to complete the model. After these refinement steps, the Rcrystal 
and Rfree converged to the values reported in Table 4.1.   
 
     4.2.8 Analysis of molecular packing in γN308K. Because γN308K involves mutation at the 
interface of adjacent fibrin units, we examined whether the substitution affects the end-to-end 
association of symmetry-related fragment D molecules. We analyzed the crystal packing of 
rfD-γN308K+GP and several known fragment D structures using MSDPisa (19). We 
determined the D:D interface in recombinant fragment D structures and compared it to those 
observed for  the naturally crosslinked double-D structure.  
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Table 4.1:       Crystallographic Data and Refinement Statistics 
Data Statistics 
     resolution (Å) 50.0 – 3.05 
     space group P43212 
     cell constants (Å) a = 95.0 
b = 95.0 
c = 448.3 
     molecules/asymmetric unit 2 
     total observations 324588 
     unique reflections 40798 
     mean redundancy 8.0 
     Rsyma (%) 14.0 (54.3) 
     completeness (%) 99.8 (99.9) 
     mean I/σ 22.8 (4.0) 
Refinement Statistics 
     Rcrystb (%) 23.5 
     Rfree c (%) 29.5 
     average B factor (Å2) 61.8 
     number of model atoms  10711 
     number of solvent sites 101 
RMS deviations from ideals  
     bond length (Å) 0.007 
     bond angles (deg) 1.04 
a Rsym = Σ|I - 〈I〉|, where I is the observed intensity and 〈I〉 is the 
average intensity of multiple symmetry-related observations of that 
reflection. b Rcryst = Σ(|Fobs|- |Fcalc|)/Σ|Fobs|, where Fobs  and Fcalc are the 
observed and calculated structure factors, respectively. c Rfree is the R-
factor based on the 5% of the data withheld from structural refinement. 
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4.3 Results 
     4.3.1 Scanning electron microscopy of clots. Previous studies examined polymerization of 
γN308K as changes in turbidity with time (7). These experiments showed γN308K had 
delayed lag times and a lower slopes compared to normal. Although the final turbidity did 
not reach plateau, it is clear from the curves that γN308K would have higher final turbidity 
compared to normal.  
     Indeed, fibers from γN308K clots had larger diameter (160 ± 45 nm) compared to normal 
(79 ± 18 nm, p < 0.05) in the absence of added calcium (Figure 4.1, Panel A). There is a 
significant increase  in the  average fiber  diameter  for  normal  clots   to  99 ± 21 nm  (p < 
0.05)  in  the presence of 5 mM calcium (Figure 4.1, Panel B) whereas those for γN308K did 
not change significantly (158 ± 40 nm, p = 0.8) but were still significantly larger than 
normal. We also compared fiber size distribution by grouping fiber diameters into bins of 10 
starting with 20 nm and ending with 300 nm. The gross distribution curve was generated 
using Origin (Northampton, MA). Fibers from normal clots had more narrow size 
distribution compared to the variant which had fibers ranging from 70-270 nm. In many 
images, thinner fibers from γN308K twist together like cables to form thicker fiber bundles.  
 
     4.3.2 Plasmin Protection Assay. To assess binding of either calcium or GPRP in γN308K, 
we performed plasmin protection assay. As previously shown, the addition of GPRP or 
calcium limits plasmin proteolysis of fibrinogen to predominantly D1 (20). In the presence of 
EDTA or in the absence of GPRP, fragment D1 is further cleaved into the smaller fragments 
D2 and D3.  As  shown in Figure 4.2A and 4.2B, fragment D1 was seen  in normal and variant  
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Figure 4.1  Scanning electron micrographs and fiber size distribution of γN308K clots. 
Fibrinogen (0.5 mg/mL) was incubated with 0.4 U/mL thrombin without added calcium 
(Panel I) and with 5 mM CaCl2 (Panel II) for 4 h at 37oC in. Images were recorded at 
101,000x (B, C, G and H) and 21,000x (D, E, I and J) magnifications. The black bar scale 
represents 100 nm for high magnification and 1 µm for lower magnification images. Black 
arrows indicate thinner fibers in γN308K that twist together like cables to form thicker fiber 
bundles. Fiber size distribution was determined by grouping fiber diameters into bins of 10 
starting with 20 nm and ending with 300 nm. The Gaussian distribution curves in (A) and (F) 
were generated using Origin.  
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 fibrinogens at 5 mM CaCl2 while in the presence of 5 mM EDTA, the smaller fragments D2 
and D3 were evident for normal and essentially only D3 in γN308K. This calcium protection 
suggests that calcium binding is normal in γN308K fibrinogen. To assess binding of GPRP to 
γN308K, we monitored proteolysis with increasing peptide concentration. At 20 µM GPRP, 
fragments D2 and D3 were  the  main  products for normal   fibrinogen; but  D1  was weakly 
evident suggesting  partial protection at this peptide concentration. The degree of protection 
increased with   increasing peptide concentration as evident from the disappearance of D2 and 
D3 and the increased intensity for D1. Hence, full protection was achieved for normal 
fibrinogen at 5 mM GPRP.  In contrast, for γN308K, partial protection was evident at peptide 
concentration ≥ 0.5 mM suggesting peptide affinity for γN308K is lower than normal. 
Although the degree of protection increased with higher peptide concentration, γN308K 
remained only partially protected even at 20 mM GPRP.  
   Plasmin cleavage in normal and γN308K fibrinogens were extensively studied by Southan 
and Yoshida et al (8, 21). Based on these two studies, we assigned digestion products and 
corresponding lysine cleavage sites in samples analyzed under reducing conditions (Figure 
4.2C and 4.2D).  Consistent with previous observations, γN308K fibrinogen was digested 
more rapidly into smaller γ-chain remnants so that more of products corresponding to the 
cleavage of γ373Lys-374Thr (γ373), γ356Lys-357Ala (γ356) and γ302Lys-303Phe (γ302) were 
observed for the variant. This faster cleavage may also be due to the additional cleavage site 
at γ308Lys (8). Note also that the γ406 remnant for γN308K had faster electrophoretic 
mobility than in  normal  fibrinogen so that it co-migrated  with  the β-chain  remnant. This is  
 
 82
  
Figure 4.2  Plasmin protection assay analyzed by SDS-PAGE. Normal recombinant or 
γN308K fibrinogen (~5 μg) containing 5 mM CaCl2, 5 mM EDTA or increasing GPRP 
concentration (supplemented with 5 mM EDTA) were incubated with either 6 μg/mL 
plasmin for 4 h at 37 °C. The digests were analyzed under nonreducing conditions using 
7.5% polyacrylamide gels (A: normal and B: γN308K). For samples analyzed under reducing 
conditions (C: normal and D: γN308K), ~10 μg of fibrinogen and 120 μg/mL of plasmin 
were used. Samples were then run in 12.5% SDS-PAGE. Plasmin cleavage degradation 
products from fibrinogen are indicated on the right. 
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not surprising as the intact γ-chain in γN308K had been shown to have faster electrophoretic 
mobility,  both  from the  recombinant protein  preparation and from purified fibrinogen from  
Kyoto I patient (4, 6). Moreover, the γ338 remnant corresponding to γ338Lys-339Cys 
cleavage was not apparent for γN308K most likely because cleavage at γ302Lys-303Phe 
precedes that of γ338Lys-339Cys as Yoshida et al. (8) earlier proposed. 
 
     4.3.3 Structure of rfD-γN308K+GP. We obtained the crystal structure of γN308K 
fragment D with GPRP at 3.1 Å (see Table 4.1). While most previously solved crystal 
structures of fragment D had an orthorhombic space group, P212121 (13, 22-24), rfD-
γN308K+GP had a tetragonal unit cell (P43212) with dimensions a = b = 95 and c = 448 Å. 
The change from asparagine to lysine at position γ308 was evident from the negative |Fo - Fc|   
density around the carboxamide group when asparagine was modeled. Structure alignment of 
normal rfD (PDB code: 1LT9) and rfD-γN308K+GP showed excellent agreement with 
RMSD of 0.731 Å over Cα-atomic positions showing that the global structure of γN308K 
fragment D was not changed by the  substitution. In both normal and γN308K structures, the 
asparagine and lysine side-chains were solvent exposed. Analysis of the charge distribution 
in the D:D interface showed increased positive charge in γN308K compared to normal 
(Figure 4.3). 
     The rfD-γN308K+GP structure showed GPRP was bound to hole “a” (Figure 4.4A). This 
was evident in the presence of electron density in |2Fo - Fc| and |Fo - Fc| maps corresponding 
to the peptide in the hole. Comparison of rfD-γN308K+GP structure with other normal 
fragment D structures showed only a subtle difference in the conformation of GPRP in hole 
“a”, well within variations  seen  in  equivalent structures.  In addition to hole “a”, GPRP was  
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Figure 4.3 Comparison of charge distribution in normal (top) and γN308K (bottom). 
There is increased positive charge for γN308K in the area where D:D interactions normally 
occur.  
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Figure 4.4 Peptide binding in rfD-γN308K+GP. Knob “A” peptide mimic, GPRP was 
bound to hole “a” in the γ-chain (A) and to hole “b” in the β-chain (B). The 2|Fo - Fc| electron 
density maps around the peptide and γ308Lys are contoured at 1.0σ. Also shown are two 
calcium ions (orange spheres) in the γ1 and β1 calcium binding sites.  
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also bound to hole “b” forming “A:b” interactions (Figure 4.4B). These “A:b” interactions 
have been seen in other fragment D structures when co-crystallized with just the knob “A” 
peptide alone (25).  
     It is well known from crystal structures that fragment D has a high-affinity calcium-
binding site in the γ chain, designated as γ1. This calcium is present in rfD-γN308K+GP and 
is about 22 Å away from γ308Lys.  Another calcium binding site analogous to γ1, located at 
an equivalent position in the β-chain (designated as β1), was also present in the structure.   
 
     4.3.4 Packing of rfD-γN308K+GP. Yang et al. have proposed that interactions in various 
crystals may be good candidates for those that occur during fiber formation (25). We 
compared the molecular packing of γN308K to normal and several variant fragment D 
structures as well as to the double-D structure where the ends are covalently crosslinked. The 
presence or absence of peptide ligands influences the space group and cell dimensions of the 
crystals. In some cases, the mutation affected the cell dimensions but the modifications 
introduced by the γN308K mutation were remarkable so that the symmetry operation was 
changed and the unit cell was doubled. In all the fragment D structures, the D:D interface 
between two fragment D molecules was analyzed from the crystal packing of symmetry 
related molecules. Consistent with observations of Everse et al. (26) in plasma fragment D 
crystals, the residues making up the D:D interface in normal recombinant fragment D were 
similar to those seen in the crosslinked double-D structure. Interestingly, fragment D crystals 
with mutations in hole “a” (rfD-γD364A) and hole “b” (rfD-BβD432A), as well as a calcium-
binding mutant (rfD-BβD398A, rfD-γE132A, not shown), also showed similar interfacial 
residues as in the normal double-D structure (Figure 4.5). In contrast, the γN308K 
 87
substitution showed different crystal packing so that the D:D interface between symmetry-
related molecules now involves new set of residues. Moreover, the D:D interactions observed 
for crosslinked double-D and the previously reported fragment D structures, are asymmetric 
so that each residue has a different set of contacts, depending on which molecule in a pair is 
being studied. In contrast, the interactions at the D:D interface in γN308K were symmetric 
and most of the contacts observed occur at the C-terminal end of the γ-chain (γ389-394). This 
observation suggests that the normal, asymmetric D:D interactions are not favorable in 
γN308K. 
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Figure 4.5 Comparison of end-to-end contacts observed in reported fragment D, rfD-
γN308K+GP and double-D structures. Analysis of the molecular packing of all fragment D 
structures except rfD-γN308K+GP showed similar asymmetric end-to-end contacts as those 
of the naturally crosslinked double-D. The residues that make up the D:D interface in the 
double-D structure are the same residues observed for all fragment D except rfD-
γN308K+GP. In contrast, rfD-γN308K+GP showed symmetric end-to-end contacts involving 
different set of residues. Potential H-bonds at the D:D interface for each structure are 
presented in the table. PDB codes for the structures are as follows: DD+BOTH (1FZC), rfD-
NL (1LT9), rfD+BOTH (1LTJ), rfD-γD364A+GP (3BVH), rfD-BβD432A+GH (3E1I). 
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4.4 Discussion 
     Taken together, our biochemical and structural studies on γN308K provide the basis for 
the impaired polymerization of this variant. Our data showed γN308K produce abnormal clot 
structure and that lysine substitution altered GPRP binding and crystal packing. As discussed 
below, our results support the following conclusions: (1) the γN308K substitution alters 
calcium binding during assembly of fibrin monomers but not in fibrinogen per se; (2) 
interactions of γ308Asn are essential to the integrity of the loop structures juxtaposed  to hole 
“a” so that GPRP binding, hence, “A:a” interactions are altered in γN308K. Moreover, our 
studies show that the γN308K fragment D crystallized in a different form with unique 
molecular packing compared to other fragment D crystals. The D:D interactions involved in 
the end-to-end association of symmetry related molecules in γN308K vary remarkably from 
those seen in all other fragment D structures suggesting that γ308Asn is critical for the 
normal end-to-end alignment of fibrin molecules. 
     Earlier investigation showed γN308K had impaired polymerization and FXIIIa-catalyzed 
crosslinking (7). These were associated with delayed FpB release, which cannot be corrected 
with increasing calcium. Indeed, both in the absence of added calcium and at 5 mM calcium, 
we showed γN308K fibers were thicker and more heterogeneous compared to normal. 
Moreover, we saw thinner fibers in γN308K twist and bundle together. Yoshida et al. (8) 
measured calcium binding to D1 fragments isolated from the heterozygous fibrinogen Kyoto I 
patient and found that calcium binding was essentially identical to normal. This is consistent 
with our observation from the plasmin protection assay where calcium imparted protection to 
both normal and γN308K from proteolytic digestion suggesting that calcium binding is 
normal in the variant. Our γN308K crystal structure further showed that all known calcium 
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binding sites in the variant fragment D were occupied at 12.5 mM. Calcium has long been 
known to have an accelerating effect on fibrin clotting. The absence of pronounced 
polymerization improvement in γN308K even at elevated calcium concentrations suggests 
that the lysine substitution either disrupts a critical aspect of fibrin assembly that involves 
calcium binding (7) or the altered polymerization overwhelms calcium dependency. In the 
crosslinked double-D structure (2), γ308Asn is within hydrogen bonding distance with 
γ321Lys which is part of the loop that binds the high affinity γ1 calcium in the adjacent 
molecule (Figure 4.6). There is no available double D structure for γN308K but 
superimposition of individual normal fragment D into the normal crosslinked double D 
structure showed that very close agreement. Hence, we modeled two γN308K fragment D 
structures into the double D structure to examine possible interactions of γ308Lys in the 
crosslinked form. The model showed very close proximity between γ308Lys and γ321Lys 
with a distance of ~2 Å, hence, steric and charge repulsion is apparent between these two 
basic residues. This repulsion is likely to induce a conformational change in the nearby γ1 
loop and destabilize calcium binding. Thus, calcium binding may be normal in fibrinogen 
and fibrin monomer but is likely altered during polymerization when fibrin molecules align 
end-to-end.  
     Polymerization lag time in γN308K is about 4-fold longer than normal suggesting slower 
protofibril initiation and formation (7, 27). Thus, introduction of a surface-exposed, 
positively-charged lysine at the normal D:D interface may not only destabilize calcium 
binding as discussed above, but the charge repulsion may also destabilize the end-to-end 
alignment of fibrin during protofibril formation. In addition, plasmin protection assay 
showed  weaker  GPRP  binding  indicating  “A:a” interactions  were  also slightly  altered in  
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Figure 4.6  Modeling γN308K+GP into the normal double-D structure. Because the 
structure of γN308K double D is not available, individual γN308K fragment D were modeled 
and superimposed into the nomal double D structure (A). The γN308K double-D model (B) 
showed very close proximity between γ308Lys and γ321Lys with a distance of ~2 Å. Steric 
and charge repulsion is apparent between these two basic residues which can likely induce 
conformational change in the nearby γ1 loop that destabilizes calcium binding. 
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γN308K. This impaired GPRP binding may not be immediately apparent as the unbound 
structure  of  γN308K  is not  available. However, comparison of the bound and unbound 
normal structures in Figure 4.7 showed very similar conformations in the γ-chain loops (L1 
and L2) that are juxtaposed to loop 3 of hole “a” (L3). This loop consists of the γ338Lys-
γ339Cys-γ340His backbone ridge that supports peptide binding. This close structural 
similarity between the bound and unbound form suggests that knob “A” binding to hole “a” 
requires minimal loop motion in the loop regions near hole “a”. It appears that the side-chain 
interactions of γ308Asn with the backbone atoms of γ270Tyr limit the flexibility of L2. 
Substitution with a bulkier lysine alters γ308Asn-γ270Tyr interaction which then affects the 
motion of adjacent loops ultimately influence knob “A” binding. While D:D interface charge 
repulsion may be the major destabilizing factor in γN308K, the altered knob “A” binding 
may also contribute to the overall impairment of protofibril formation. Indeed, γN308K 
produced thicker fibers than normal suggesting slow formation of stable protofibrils; that 
these few existing protofibrils grow longer and aggregate laterally resulting in a network of 
thicker fibers. 
     Protein-protein contacts such as those appearing in the crystallization of proteins are 
generally considered non-specific on the basis of the wide polymorphism exhibited by 
protein molecules (28). Nevertheless, protein crystals are also stable physical phases so that 
molecular packing in the crystal may represent stable states that mimic physiologically-
relevant protein-protein interactions. This is true for the D:D interfacial interactions that are 
involved in the end-to-end association of fibrin molecules (26). Molecular packing analysis 
of all previously reported normal and variant fragment D structures showed individual 
fragment  D molecules  form the same D:D interface  so that  the end-to-end  associations are  
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Figure 4.7 Comparison of bound and unbound forms of normal and γN308K. The 
conformations of γ-chain loops L1, L2, L3 and L4 are similar in the normal unbound (A), 
normal bound (B) and γN308K bound (C) structures suggesting that knob “A” binding to 
hole “a” requires minimal motion in surrounding loops. It appears that the side-chain 
interactions of γ308Asn with the backbone atoms of γ278Tyr limit the flexibility of L2. 
Substitution with a bulkier lysine likely alters γ308Asn-γ278Tyr interaction which then 
affects the motion of adjacent loops ultimately influence knob “A” binding. 
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similar to those in the naturally crosslinked human fibrin (double-D). It is therefore 
remarkable that the γN308K mutation disrupted this  normal  asymmetric, end-to-end 
association of fragment D molecules and formed a different, symmetric crystal packing 
interactions. Whether or not this end-to-end association occurs physiologically is uncertain 
since the crosslinked double D counterpart of γN308K in not available and the detailed 
contacts between the D and E regions are not currently known.  Nevertheless, a proposed 
model of the protofibril based on the structures of chicken fibrinogen and human double D, 
constructed by Yang et al. (25), may provide some insights. In this model, the distance 
between two strands of the protofibril was estimated to be ~80 Å. By maintaining this 
distance between parallel molecular axes and by modeling the D:D interfaces observed in the 
normal double D structure and in γN308K into the chicken fibrinogen structure, the positions 
of “A:a” knob-hole interactions relative to the central E region may be reasonably estimated 
(Figure 4.8). Based on this model, the D:D association in the normal double D structure 
allows close proximity between two adjacent holes “a” such that the distance between the 
bound knob A (α17-20) to the central E region is within the extended length of 6 residues 
(which are missing in the structure) and within the constraints imposed by the α28Cys-
α28Cys disulfide bond. In γN308K, the different D:D interface puts the two holes “a” on 
opposite sides of the junction approximately 50 Å away from the central E region, a distance 
that α17-26 can not span given the constraints of the α28Cys disulfide bond. All these 
observations suggest that the new D:D interface observed from the molecular packing of 
γN308K is more favorable for end-to-end abutment of fibrin molecules but is not amenable 
for “A:a” interactions to occur. It is likely that during polymerization, γN308K forms the 
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D:D interface seen in normal crosslinked fibrin albeit charge repulsion and possible 
destabilization of the γ1 calcium binding loop, as discussed above. 
In summary, analysis of γN308K fibrinogen suggests that γ308Asn is critical not only 
for charge complementarity of the D:D interface during end-to-end association of fibrin 
molecules but also important in preserving the structural integrity of loops that influence 
“A:a” knob-hole interactions and calcium binding. All these factors contribute to the 
impaired polymerization and abnormal clot structure of γN308K. 
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Figure 4.8 Models of protofibril interactions in normal and γN308K. The D:D 
association in normal double D structure (A)  allows close proximity between two adjacent 
holes “a” such that the distance between the bound knob A (α17-20) to the central E region is 
within the extended length of 6 residues (missing in the structure) and within the constraints 
imposed by the α28Cys-α28Cys disulfide bond. In γN308K (B), the different D:D interface 
puts the two holes “a” in opposite sides of the junction approximately 50 Å away from the 
central E region, a distance that α17-26 can unlikely span given the constraints of the 
α28Cys disulfide bond. These suggest that the D:D interface observed from the molecular 
packing of γN308K is more favorable for end-to-end abutment of fibrin molecules but is not 
amenable for “A:a” interactions. 
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CHAPTER 5 
 
 
 
SUMMARY AND FUTURE DIRECTIONS OF THIS RESEARCH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1 Summary 
    The work detailed in this dissertation combines biochemical assays and X-ray 
crystallography to deepen the current understanding of the mechanism of fibrin 
polymerization. In Chapter 2, we solved the crystal structure of fragment D from γD364A to 
understand the molecular basis for the aberrant function of γ364Asp variants. 
Crystallographic studies revealed γ364Asp is part of hole “a” that interacts with knob “A” 
peptide mimic, GPRP. Biochemical studies have shown γ364Asp is critical to 
polymerization, based on the observation that the polymerization of variants γD364A, 
γD364H and γD364V is exceptionally impaired (1). Surprisingly, the structure (rfD-
γD364A+GP) showed near normal “A:a” interactions with GPRP bound to hole “a” and no 
change in the overall structure of γD364A (2). Of note, inspection of the structure showed 
that the negative electrostatic potential inside hole “a” was diminished by this substitution. 
We examined GPRP binding to the γ364Asp variants in solution by plasmin protection assay 
and found no protection of either γD364H or γD364V but partial protection of γD364A, 
indicating the peptide does not bind detectably to either γD364H or γD364V and binds more 
weakly than normal to γD364A. We also examined protection by calcium and found all 
variants were indistinguishable from normal suggesting the global structures of the variants 
are not markedly different from normal. The prolonged lag time during thrombin-catalyzed 
polymerization suggests slow protofibril formation in γD364A which may be a consequence 
of the diminished electrostatic steering due to the loss of the acidic γ364Asp; that the local 
negative charge on holes “a” reinforce electrostatic steering so that knobs “A” at the center of 
one molecule are able to find the holes at the terminal ends of another molecule during 
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protofibril formation.  Our data imply that γ364Asp per se  is not required for knob “A” 
binding to hole “a”; rather, this residue’s negative charge has a critical role in the 
electrostatic interactions that facilitate the important first step in fibrin polymerization.  
     The importance of “B:b” knob-hole interactions remain unclear from conflicting 
biochemical data (3-8). In Chapter 3, we used recombinant variant BβD432A to shed light 
into this controversy. Fibrinogen residue Bβ432Asp is part of hole “b” that interacts with 
knob “B” whose sequence starts with GHRP. Because previous studies showed BβD432A 
has normal polymerization, we hypothesized that Bβ432Asp is not critical for knob “B” 
binding and that new knob-hole interactions would compensate for the loss of this Asp 
residue. To test this hypothesis, we solved the crystal structure of fragment D from 
BβD432A. Surprisingly, the structure (rfD-BβD432A+GH) showed the peptide GHRP was 
not bound to hole “b”. We then re-evaluated the polymerization of this variant by examining 
clot turbidity, clot structure and the rate of FXIIIa-crosslinking. The turbidity and the rate of 
γ-γ dimer formation for BβD432A were indistinguishable compared to normal fibrinogen. 
Scanning electron microscopy showed no significant differences between the clots of 
BβD432A and normal fibrinogen, but the thrombin-derived clots had thicker fibers than clots 
obtained from batroxobin, suggesting that cleavage of FpB is more important than “B:b” 
interactions. The normal polymerization of BβD432A, despite, the absence of “B:b” 
interactions suggests that occupancy of hole “b” may have little impact on polymerization; it 
is the loss of the negatively-charged FpB which relieves charge repulsion, rather than the 
gain of “B:b” interactions that is critical. Hence, electrostatic factors are more critical than 
actual “B:b” knob-hole binding in fibrin polymerization. 
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     In addition to the knob-hole binding, other interactions like the end-to-end associations 
mediated by the D:D interface stabilize fibrin polymerization. Unlike knob-hole interactions, 
D:D interfacial interactions are not well-studied. In Chapter 4, we examined the role of D:D 
interactions in fibrin polymerization using a variant recombinant fibrinogen, γN308K, 
patterned after a naturally occurring dysfibrinogen. Previous studies of this variant showed 
impaired polymerization that was not improved by increasing calcium ion concentrations (9). 
We combined biochemical and structural data to provide the molecular basis for the 
impairment seen in γN308K. Plasmin protection assays showed γN308K require higher 
concentration of the knob “A” peptide mimic (GPRP) to achieve partial protection from 
digestion suggesting that γN308K has slightly impaired “A:a” interactions. Calcium ions 
imparted protection to γN308K similar to normal fibrinogen suggesting calcium ion binding 
was not altered in the variant. However, modeling the D:D interactions seen in normal 
crosslinked fibrin for γN308K showed potential steric and charge repulsion between γ308Lys 
and γ321Lys that may destabilize the γ1 calcium binding loop. Analysis of the electrostatic 
potential in the area where D:D interactions normally occur showed increased positive charge 
in γN308K suggesting possible repulsion between abutting fibrin molecules. Indeed, 
molecular packing in rfD-γN308K+GP crystals showed symmetric D:D contacts involving 
residues different from those observed in all previously reported fragment D and naturally 
crosslinked double D structures. In conclusion, analysis of γN308K fibrinogen suggests that 
γ308Asn is critical not only for charge complementarity of the D:D interface during end-to-
end association of fibrin molecules but also important  for “A:a” knob-hole interactions and 
calcium binding. 
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5.2 Future Directions of this Research 
    Despite a deeper understanding of the mechanism of fibrin polymerization provided by 
this research, many unanswered questions remain. We have shown that “B:b” interactions 
have little influence on polymerization, particularly during lateral aggregation of protofibrils. 
Questions then arise: (1) What molecular events substantially modulate lateral aggregation?; 
and (2) When are “B:b” interactions important?  
     5.2.1 Investigation of the molecular events that modulate lateral aggregation. In Chapter 
3, the role of “B:b” interactions was studied using a variant fibrinogen, BβD432A, with 
impaired hole “b”. The crystal structure showed BβD432A does not bind knob “B” peptide 
mimic GHRP. Nevertheless, BβD432A has normal polymerization suggesting that “B:b: 
interactions are not critical for polymerization, specifically in lateral aggregation. Based on 
this research, we propose that the release of the electronegative FpB minimizes electrostatic 
repulsion and promote lateral association.  
     Many have shown that calcium modulates fibrin polymerization (10-13).  Calcium 
binding at the β2 site is related to “B:b” interactions in that both processes involve 
Bβ398Asp. Recall from Chapter 3 that this residue, together with Bβ397Glu, is part of the 
loop that flips 180o between coordinating the β2 calcium located away from hole “b” and 
binding the knob in hole “b” (see Figure 3.3). Another residue that is critical to β2 calcium 
binding but is not part of hole “b” is γ132Glu. Both BβD398A and BβD432A, but not 
γE132A, have impaired hole “b” (14, 15). On the other hand, both BβD398A and γE132A, 
but not BβD432A have altered β2 calcium binding. At different calcium concentrations, 
BβD432A had normal turbidity while BβE397A and BβD398A were markedly less turbid 
than normal. Interestingly, γE132A showed uncharacteristic enhancement of turbidity at 
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calcium  ion concentrations ≤ 1 mM but was indistinguishable from normal fibrinogen at 10 
mM (15). It has been suggested that γE132A has enhanced lateral aggregation due to more 
favored “B:b” interactions as the weakened β2 binding would decrease competition for 
Bβ398Asp. Because our data on BβD432A presented in Chapter 3 indicate that “B:b” 
interactions are not critical for polymerization, the enhanced lateral aggregation of γE132A at 
lower calcium concentration may be due to altered β2 binding  per se and is likely to be 
independent of “B:b” interactions. It is likely that the extra flexibility gained by the βC 
domain when β2 calcium anchor is weakened, allows more freedom for domain motion 
which establish secondary interactions (16) as shown in Figure 5.1. Doolittle et al. (17) 
suggested that βC-βC interactions between different protofibrils can likely occur and may 
contribute greatly to the increased turbidity of γE132A. BβD398A also has impaired β2 
calcium binding but the effect on polymerization is quite the opposite of that seen with 
γE132A, with BβD398A being less turbid than normal.  It was earlier suggested that this 
impairment in BβD398A was due to absence of “B:b” interactions as hole “b” in this variant 
does not bind GHRP (14).  Because BβD432A had normal turbidity even with impaired hole 
“b”, it is likely that the conformational change (i.e. flipping) associated with Bβ397Glu and 
Bβ398Asp, not actual “B:b” binding, influences polymerization. It appears then that the 
effect on lateral aggregation is different when only β2 is impaired versus when both the 
movable flap and the β2 are abnormal. In the absence of peptides, fragment D crystals were 
obtained at 70 mM calcium (about 35 times the physiological concentration) so that the 
structures always showed calcium bound to the β2 site even in β2 mutants (albeit with less 
occupancy and/or missing one coordination). While such a structure is representative of one 
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conformation, a fraction of molecules without calcium bound at β2 could also exist in 
equilibrium such that the residues Bβ397Glu and Bβ398Asp are likely to be more dynamic in 
this conformation. Whether or not knob-hole binding is possible, it is likely that the flipping 
of Bβ397Glu and Bβ398Asp also contribute to normal polymerization. Although not visible 
in static crystal structures, perhaps this local conformational change influences parts of the 
βC-module or the nearby coiled coil region that may modulate polymerization.  
     Studies also suggest the flexible αC domains have an important role in polymerization. A 
variant fibrinogen, Aα251, truncated at residue 251, lacks the αC domains. Lateral 
aggregation of Aα251 was only modestly impaired and produced clots that are denser and 
have thinner fibers compared to normal (18). In another study, polymerization of fibrinogen 
fragment X, which lacks the αC domains, is impaired such that fibers formed were thicker 
than normal (19). Thus, the αC domains may be modulating lateral aggregation, likely 
through nonspecific intermolecular αC-αC interactions between protofibrils  as shown in 
Figure 5.2 (18).  
     Putting the new findings presented in this dissertation in context with previous studies, it 
appears that four molecular events likely modulate lateral aggregation: (1) electrostatic 
factors resulting from removal of FpB; (2) presence of the β2 calcium and the βC-βC 
interactions resulting from large-scale domain movement after disruption of β2; (3) the 
conformational change associated with flipping of Bβ397Glu and Bβ398Asp; and (4) αC-αC 
interactions. The question is the relative impact of each of these events to polymerization, 
that is, which is the most and which is the least important. 
     Experiments using hybrid variants may provide a clear answer to this question. The triple 
variant Aα251, BβD398A and γE132A will eliminate αC-αC, “B:b” interactions and β2 
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calcium so that only FpB release makes major contribution to lateral aggregation. Doubly-
substituted variants combining Aα251 and BβD432A (without both αC-αC and “B:b” 
interactions) may also be synthesized to fully appreciate the effect of  β2 calcium and the 
flipping of Bβ397Glu and Bβ398Asp. The impact of the Bβ397Glu and Bβ398Asp flipping 
to polymerization can also be studied by limiting or completely eradicating the movement of 
this movable flap. Note that Bβ397Glu and Bβ398Asp are followed by a Gly-Gly-Gly 
sequence (Bβ399-401) which would contribute to the flexibility of this loop. The variant 
BβG399P,G400P,G401P where the new prolines now flank the movable flap is anticipated to 
limit if not eradicate motion of this loop. This variant can then be combined with Aα251 and/ 
or γE132A to evaluate role of specific events in lateral aggregation. By comparing the results 
obtained from all these new and hybrid variants, the molecular events modulating lateral 
aggregation will be more fully defined. 
 
     5.2.2 When are “B:b” interactions important? Previous studies showed “B:b” interactions 
are critical for polymerization when hole “a” is compromised and “A:a” interactions are 
absent of severely impaired (1). In Chapter 3, we mentioned some preliminary studies done 
to investigate the role of “B:b” interactions in the lysis of the clot. These experiments were 
based on previous studies by Doolittle and Pandi (17) which showed that addition of various 
knob “B” peptide mimics delay fibrinolysis. Based on these observations, Doolittle and Pandi 
(16) proposed that the conformational changes associated with “B:b” interactions  enhance 
fibrinolysis, as shown in Figure 5.3. Because knob “B” is tethered to the center of the 
molecule, its binding to hole “b” locks the βC domain into a conformation that exposes a 
tPA/plasminogen binding site in the coiled-coil region (Figure 5.3C). When a free, 
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untethered knob “B” peptide mimic like GHRPL or GHRPY (patterned after human and 
bovine knob “B”, respectively) is added to the system, it competes with the authentic, 
tethered knob “B”. Because the added peptide is untethered, it’s binding to hole “b” does not 
induce the same conformational change that a tethered knob does (Figure 5.3B). Hence, the 
addition of peptides favors the situation depicted in Figure 5.3B rather than Figure 5.4C, 
likely delaying clot lysis by limiting accessibility to a tPA/plasminogen binding site. 
     To further investigate this phenomenon, similar experiments using the variant BβD432A 
can be done. We have shown that hole “b” in this variant is impaired. Because GHRP does 
not exclusively bind to hole “b”, that is, it can also bind to hole “a” (14), another peptide that 
exclusively binds to hole “b” should be used. The knob “B” peptide mimic AHRP, patterned 
after the knob “B” sequence in chicken fibrin, has been shown to bind exclusively to hole “b” 
(20). The role of β2 calcium ion in fibrinolysis can also be investigated using the variants 
BβD398A and γE132A. Further, the role of knob “B” per se, in fibrinolysis can be examined 
by using batroxobin (that cleaves FpA only, hence, no “B:b” interactions) to initiate clot 
formation before lysis. Variant fibrinogens with very severe to no FpB cleavage can also be 
used in these lysis experiments. These studies may provide further insights into the role of 
“B:b” interactions in fibrinolysis. 
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Figure 5.1 Schematic representation of the possible βC domain movement. (A) The 
presence of the β2 calcium (orange sphere) restricts the movement of the βC domain (green). 
(B) When the β2 calcium site is disrupted, the βC domain gains freedom to move about and 
establish secondary interactions, likely with another βC domain in the same or different 
protofibril which can enhance turbidity. (C) The βC domain movement may also enhance the 
capture of hole “b” by the long, tethered knob “B”. 
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αC-αC 
interactions 
 
Figure 5.2 Schematic representation of the proposed role of αC domains in fibrin 
polymerization. The αC domains (red) likely associate intermolecularly with other αC 
domains in another protofibril, thus, promoting lateral aggregation. The γ- and β-chains are 
colored blue and green, respectively.  
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Figure 5.3 Schematic representation of the conformational change in the βC domain. 
(A) When knob “B” is not bound to hole “b”, the β2 calcium (orange circle) is bound 
blocking access to a tPA/plasminogen (tPA/Pg) binding site in the coiled coil region 
(yellow). (B) Binding of the untethered knob “B” peptide mimetic to hole “b” disrupts the β2 
calcium binding but does not allow full access to the tPA/Pg binding site. (C) Binding of the 
authentic and tethered knob “B” locks the βC domain to a conformation that allows full 
accessibility to the tPA/Pg binding site. In the fibrinolysis experiments by Doolittle and 
Pandi (17), addition of peptides likely favors (B) rather than (C), thereby inhibiting clot lysis.  
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